<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1112246405
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ROXARDIO 20MG F.C.TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ROSUVASTATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        47.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LEK S.A" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LEK S.A
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SANDOZ
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AA07 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Roxardio belongs to a group of medicines called statins (HMG-CoA reductase inhibitors).</p><p>&nbsp;</p><p>You have been prescribed Roxardio because:</p><p>&middot;&nbsp; &nbsp;You have a <strong>high cholesterol level</strong>. This means you are <strong>at risk from a heart attack or stroke</strong>. Roxardio is used in adults, adolescents and children 6 years or older to treat high cholesterol.</p><p>&nbsp;</p><p>You have been advised to take a statin, because changing your diet and taking more exercise were not enough to correct your cholesterol levels. You should continue with your cholesterol-lowering diet and exercise while you are taking Roxardio .</p><p>&nbsp;</p><p>Or</p><p>&nbsp;</p><p>&middot;&nbsp; &nbsp;You have other factors that increase your risk of having a heart attack, stroke or related health problems.</p><p>&nbsp;</p><p>Heart attack, stroke and other problems can be caused by a disease called atherosclerosis. Atherosclerosis is due to build up of fatty deposits in your arteries.</p><p>&nbsp;</p><p><strong>Why is it important to keep taking </strong><strong>Roxardio ?</strong></p><p>Roxardio is used to correct the levels of fatty substances in the blood called lipids, the most common of which is cholesterol.</p><p>There are different types of cholesterol found in the blood &ndash; &lsquo;bad&rsquo; cholesterol (low-density lipoprotein cholesterol, or LDL-C) and &lsquo;good&rsquo; cholesterol (high-density lipoprotein cholesterol, or HDL-C).</p><p>&nbsp;</p><p>&middot;&nbsp; &nbsp;Roxardio can reduce the &quot;bad&quot; cholesterol and increase the &quot;good&quot; cholesterol.</p><p>&middot;&nbsp; &nbsp;It works by helping to block your body&rsquo;s production of &lsquo;bad&rsquo; cholesterol and improves your body&rsquo;s ability to remove it from your blood.</p><p>&nbsp;</p><p>For most people, high cholesterol does not affect the way they feel because it does not produce any symptoms. However, if it is left untreated, fatty deposits can build up in the walls of your blood vessels causing them to narrow.</p><p>Sometimes, these narrowed blood vessels can get blocked which can cut off the blood supply to the heart or brain leading to a heart attack or a stroke. If you correct your cholesterol levels, you can reduce your risk of having a heart attack or stroke. By lowering your cholesterol levels, you can reduce your risk of having a heart attack, a stroke or related health problems.</p><p>&nbsp;</p><p>You <strong>need to</strong> <strong>keep taking </strong>Roxardio , even if it has got your cholesterol to the right level, because <strong>it prevents your cholesterol levels from creeping up again </strong>and causing build up of fatty deposits. However, you should stop if your doctor tells you to do so, or you have become pregnant.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Roxardio :&nbsp; </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are <strong>allergic</strong> <strong>to rosuvastatin</strong> or any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are <strong>pregnant </strong>or<strong> breast-feeding. </strong>If you become pregnant while taking Roxardio <strong>stop taking it immediately </strong>and tell your doctor. Women should avoid becoming pregnant while taking Roxardio by using suitable contraception.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have <strong>liver disease. </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have <strong>severe kidney problems.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have <strong>repeated or unexplained muscle aches or pains</strong> (myopathy).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take<strong> a drug combination of sofosbuvir/velpatasvir/voxilaprevir </strong>(used for viral infection of the liver called hepatitis C).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take a medicine named <strong>ciclosporin</strong> (used, for example, after organ transplants).</p><p>Roxardio Roxardio</p><p>If any of the above applies to you (or you are in doubt), <strong>please go back and see your doctor.</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>In addition, do not take the 40 mg dose of Roxardio (the highest dose):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had <strong>any repeated or unexplained muscle aches or pains</strong> (myopathy), a personal or family history of muscle problems, or a previous history of muscle problems when taking other cholesterol-lowering medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have <strong>moderate kidney problems</strong> (if you are in doubt, please ask your doctor).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your <strong>thyroid gland</strong> is not working properly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you <strong>regularly drink large amounts of alcohol.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take <strong>other medicines called</strong> <strong>fibrates</strong> to lower your cholesterol.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If <strong>you are of Asian origin</strong> &ndash; (Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).</p><p>If any of the above applies to you (or you are in doubt), <strong>please go back and see your doctor.</strong></p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking <strong>Roxardio :</strong>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have <strong>problems with your kidneys.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have <strong>problems with your liver.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have<strong> severe respiratory failure.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you <strong>have had repeated or unexplained muscle aches or pains</strong> (myopathy), a personal or family history of muscle problems or a previous history of muscle problems when taking other cholesterol-lowering medicines. Tell your doctor immediately if you have unexplained muscle aches or pains especially if you feel unwell or have a fever. Also tell your doctor or pharmacist if you have a muscle weakness that is constant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you <strong>regularly drink large amounts of alcohol.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your <strong>thyroid gland</strong> is not working properly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take <strong>other medicines called fibrates</strong> to lower your cholesterol.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take <strong>medicines used to treat the HIV infection </strong>(e.g. ritonavir with lopinavir, atazanavir and/or tipranavir), please see Other medicines and Roxardio .</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking or have taken in the last 7 days a medicine called fusidic acid (a medicine for bacterial infection) orally or by injection. The combination of fusidic acid and rosuvastatin can lead to serious muscle problems (rhabdomyolysis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are<strong> over 70 years of age </strong>(as your doctor needs to choose the right start dose of Roxardio to suit you).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are <strong>of Asian origin</strong> &ndash; that is Japanese, Chinese, Filipino, Vietnamese, Korean and Indian. Your doctor needs to choose the right start dose of Roxardio to suit you.</p><p>&middot;<strong> If you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after taking rosuvastatin or other related medicines.</strong><strong> </strong>Serious skin reactions including Stevens-Johnson syndrome and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in association with rosuvastatin treatment. Stop using &nbsp;Roxardio and seek medical attention immediately if you notice any of the symptoms described in section 4.</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If the patient is under 6 years old:</strong> Roxardio should not be given to children younger than 6 years.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If the patient is below 18 years of age:</strong> The Roxardio 40 mg is not suitable for use in children and adolescents below 18 years of age.</p><p><strong>&nbsp;</strong></p><p>If any of the above applies to you (or if you are not sure):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not take Roxardio 40mg (the highest dose) and check with your doctor or pharmacist before you actually start taking any dose of Roxardio .</strong></p><p><strong>&nbsp;</strong></p><p>In a small number of people, statins can affect the liver. This is identified by a simple test which looks for increased levels of liver enzymes in the blood. For this reason, your doctor will usually carry out this blood test (liver function test) before and during treatment with Roxardio .</p><p><strong>&nbsp;</strong></p><p>While you are on this medicine your doctor will monitor you closely if you have diabetes or are at risk of developing diabetes. You are likely to be at risk of developing diabetes if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure.</p><p>&nbsp;</p><p><strong>Other medicines and Roxardio </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p><strong>&nbsp;</strong></p><p><strong>If you need to take oral fusidic acid to treat a bacterial infection you will need to temporarily stop using this medicine. Your doctor will tell you when it is safe to restart Roxardio . Taking Roxardio with fusidic acid may rarely lead to muscle weakness, tenderness or pain (rhabdomyolysis). See more information regarding rhabdomyolysis in section 4.</strong></p><p><strong>&nbsp;</strong></p><p>Tell your doctor if you are taking any of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ciclosporin</strong> (used for example, after organ transplants)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>warfarin or clopidogrel </strong>or any other medicine used for thinning the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>fibrates and other lipid-lowering products</strong> (such as gemfibrozil, fenofibrate)<strong> </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>any other medicine used to lower cholesterol</strong> (such as ezetimibe)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>indigestion remedies</strong> (used to neutralise acid in your stomach)<strong> </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>erythromycin </strong>(an antibiotic)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>an oral contraceptive</strong> (the pill)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>hormone replacement therapy</strong><strong><u> </u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>regorafenib </strong>(used to treat cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>darolutamide</strong> (used to treat cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any of the following <strong>medicines used to treat viral infections,</strong> including HIV or hepatitis C infection, alone or in combination (please see Warnings and precautions): ritonavir, lopinavir, atazanavir, sofosbuvir, voxilaprevir, ombitasvir, paritaprevir, dasabuvir, velpatasvir, grazoprevir, elbasvir, glecaprevir, pibrentasvir</p><p>&nbsp;</p><p>The effects of these medicines could be changed by Roxardio or they could change the effects of Roxardio .</p><p><strong>&nbsp;</strong></p><p><strong>Roxardio </strong><strong>with food and drink</strong></p><p>You can take Roxardio with or without food.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Do not take Roxardio </strong>if you are pregnant or breast-feeding. If you become pregnant while taking Roxardio <strong>stop taking it immediately </strong>and tell your doctor. Women should avoid becoming pregnant while taking Roxardio by using suitable contraception.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>Most people can drive a car and operate machinery while taking Roxardio &ndash; it will not affect their ability. However, some people feel dizzy during treatment with Roxardio . If you feel dizzy, consult your doctor before attempting to drive or use machines.</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p><strong>Roxardio contains lactose and sodium</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>Usual doses in adults</strong></p><p><strong>&nbsp;</strong></p><p><strong>If you are taking </strong><strong>Roxardio for high cholesterol:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Starting dose</strong></p><p>Your treatment with Roxardio must start with the <strong>5 mg or the 10 mg dose</strong>, even if you have taken a higher dose of a different statin before. The choice of your start dose will depend upon:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your cholesterol level</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the level of risk you have of experiencing a heart attack or stroke</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; whether you have a factor that may make you more sensitive to possible side effects.</p><p>Please check with your doctor or pharmacist which start dose of Roxardio will best suit you.</p><p>&nbsp;</p><p>Your doctor may decide to give you the lowest dose (5 mg) if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are of Asian origin (Japanese, Chinese, Filipino, Vietnamese, Korean and Indian)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are over 70 years of age</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have moderate kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are at risk of muscle aches and pains (myopathy).</p><p>&nbsp;</p><p><strong>Increasing the dose and maximum daily dose</strong></p><p>Your doctor may decide to increase your dose. This is so that you are taking the amount of Roxardio that is right for you. If you started with a 5 mg dose, your doctor may decide to double this to 10 mg, then to 20 mg and then 40 mg if necessary. If you started on 10 mg, your doctor may decide to double this to 20 mg and then 40 mg if necessary. There will be a gap of four weeks between every dose adjustment.</p><p>The maximum daily dose of Roxardio is 40 mg. It is only for patients with high cholesterol levels and a high risk of heart attacks or stroke whose cholesterol levels are not lowered enough with 20 mg.</p><p><strong><em>&nbsp;</em></strong></p><p><strong>If you are taking </strong><strong>Roxardio to reduce your risk of having a heart attack, stroke or related health problems:</strong></p><p><strong>&nbsp;</strong></p><p>The recommended dose is 20 mg daily. However, your doctor may decide to use a lower dose if you have any of these factors mentioned above.</p><p>&nbsp;</p><p><strong>Use in children and adolescents aged 6 &ndash; 17 years</strong></p><p>The usual start dose is 5 mg. Your doctor may increase your dose to find the right amount of Roxardio for you. The maximum daily dose of Roxardio is 10 mg for children aged 6 to 9 years and 20 mg for children aged 10 to 17 years. Take your dose once a day. Roxardio <strong>40 mg </strong>tablet should <strong>not </strong>be used by children.</p><p><strong><em>&nbsp;</em></strong></p><p><strong>Taking your tablets</strong></p><p>Swallow each tablet whole with a drink of water.</p><p>Take <strong>Roxardio </strong>once daily. You can take it at any time of the day with or without food.</p><p>Try to take your tablet at the same time every day to help you to remember it.</p><p>&nbsp;</p><p><strong>Regular cholesterol checks</strong></p><p>It is important to go back to your doctor for regular cholesterol checks to make sure your cholesterol has reached and is staying at the correct level.</p><p>Your doctor may decide to increase your dose so that you are taking the amount of Roxardio that is right for you.</p><p>&nbsp;</p><p><strong>If you take more </strong><strong>Roxardio </strong><strong>than you should</strong></p><p>Contact your doctor or nearest hospital for advice.</p><p>&nbsp;</p><p>If you go into hospital or receive treatment for another condition, tell the medical staff that you&rsquo;re taking Roxardio .</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take </strong><strong>Roxardio </strong></p><p>Don&rsquo;t worry, just take your next scheduled dose at the correct time. Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking </strong><strong>Roxardio </strong></p><p>Talk to your doctor if you want to stop taking Roxardio . Your cholesterol levels might increase again if you stop taking Roxardio .</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>It is important that you are aware of what these side effects may be. They are usually mild and disappear after a short time.</p><p>&nbsp;</p><p><strong>Stop taking Roxardio and seek medical help immediately</strong> if you have any of the following allergic reactions:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in breathing, with or without swelling of the face, lips, tongue and/or throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, tongue and/or throat, which may cause difficulty in swallowing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe itching of the skin (with raised lumps)</p><p>&nbsp;</p><p><strong>Also, stop taking Roxardio and talk to your doctor immediately if you have: </strong></p><ul><li><strong>any unusual aches or pains </strong>in your muscles which go on for longer than you might expect. Muscle symptoms are more common in children and adolescents than in adults. As with other statins, a very small number of people have experienced unpleasant muscle effects and rarely these have gone on to become a potentially life threatening muscle damage known as <em>rhabdomyolysis</em>.</li><li>lupus-like disease syndrome (including rash, joint disorders and effects on blood cells)</li><li>muscle rupture</li><li>reddish non-elevated, target-like or circular patches on the trunk, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes. These serious skin rashes can be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome).</li><li>widespread rash, high body temperature and enlarged lymph nodes (DRESS syndrome or drug hypersensitivity syndrome).</li></ul><p><strong>&nbsp;</strong></p><p><strong>Common side effects </strong>(may affect up to 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick&nbsp;&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an increase in the amount of protein in the urine &ndash; this usually returns to normal on its own without having to stop taking your Roxardio tablets (only Roxardio 40 mg)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diabetes &ndash; this is more likely if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure. Your doctor will monitor you while you are taking this medicine.</p><p>&nbsp;</p><p><strong>Uncommon side effects </strong>(may affect up to 1 in 100 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash, itching or other skin reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an increase in the amount of protein in the urine &ndash; this usually returns to normal on its own without having to stop taking your Roxardio tablets (only Roxardio 5 mg, 10 mg and 20 mg).</p><p>&nbsp;</p><p><strong>Rare side effects </strong>(may affect up to1 in 1,000 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe allergic reaction &ndash; signs include swelling of the face, lips, tongue and/or throat, difficulty in swallowing and breathing, a severe itching of the skin (with raised lumps). <strong>If you think you are having an allergic reaction, then stop taking Roxardio </strong>and seek medical help immediately</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle damage in adults &ndash; as a precaution, <strong>stop taking Roxardio and talk to your doctor immediately if you have any unusual aches or pains</strong> in your muscles which go on for longer than expected</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a severe stomach pain (inflamed pancreas)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in liver enzymes in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual bruising and bleeding due to low level of blood platelets.</p><p><strong>&nbsp;</strong></p><p><strong>Very rare side effects </strong>(may affect up to 1 in 10,000 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; jaundice (yellowing of the skin and eyes)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hepatitis (an inflamed liver)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; traces of blood in your urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; damage to the nerves of your legs and arms (such as numbness)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; memory loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gynecomastia (breast enlargement in men).</p><p><strong>&nbsp;</strong></p><p><strong>Side effects of </strong><strong>not known frequency </strong>(frequency cannot be estimated from the available data):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea (loose stools)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oedema (swelling)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleep disturbances, including insomnia and nightmares</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sexual difficulties</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathing problems including persistent cough and/or shortness of breath or fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tendon disorders, sometimes complicated by rupture</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness that is constant.</p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To report any side effect(s)</p><p>&middot;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_16" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;margin-left:0;margin-top:11.3pt;
 width:429pt;height:104.9pt;z-index:251659264;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:left;
 mso-position-horizontal-relative:margin;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:margin;mso-height-relative:margin;v-text-anchor:top'
 o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" fillcolor="window" strokeweight=".5pt">
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoPlainText><span style='mso-spacerun:yes'> </span>NPC contact
    information Saudi Arabia:<o:p></o:p></p>
    <p class=MsoPlainText><o:p>&nbsp;</o:p></p>
    <p class=MsoPlainText style='margin-left:.5in;text-indent:-.25in;
    mso-list:l1 level1 lfo11'><![if !supportLists]><span style='font-family:
    "Courier New";mso-fareast-font-family:"Courier New"'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span>The National
    Pharmacovigilance Centre (NPC):<o:p></o:p></p>
    <p class=MsoPlainText style='margin-left:.5in;text-indent:-.25in;
    mso-list:l1 level1 lfo11'><![if !supportLists]><span style='font-family:
    "Courier New";mso-fareast-font-family:"Courier New"'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span>SFDA Call Center: 19999<o:p></o:p></p>
    <p class=MsoPlainText style='margin-left:.5in;text-indent:-.25in;
    mso-list:l1 level1 lfo11'><![if !supportLists]><span style='font-family:
    "Courier New";mso-fareast-font-family:"Courier New"'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span>E-mail: <a
    href="mailto:npc.drug@sfda.gov.sa">npc.drug@sfda.gov.sa</a><o:p></o:p></p>
    <p class=MsoPlainText style='margin-left:.5in;text-indent:-.25in;
    mso-list:l1 level1 lfo11'><![if !supportLists]><span style='font-family:
    "Courier New";mso-fareast-font-family:"Courier New"'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span>Website ade.sfda.gov.sa<o:p></o:p></p>
    <p class=MsoNormal><span style='font-family:"Arial Unicode MS",serif;
    mso-fareast-font-family:"Arial Unicode MS";mso-bidi-font-family:"Arial Unicode MS"'><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap anchorx="margin"/>
</v:shape><v:shape id="Text_x0020_Box_x0020_4" o:spid="_x0000_s1028" type="#_x0000_t202"
 style='position:absolute;margin-left:.3pt;margin-top:129.2pt;width:429pt;
 height:89.25pt;z-index:251661312;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:margin;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:margin;mso-height-relative:margin;v-text-anchor:top'
 o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" fillcolor="window" strokeweight=".5pt">
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:2.0pt;margin-right:0in;margin-bottom:
    2.0pt;margin-left:0in;mso-add-space:auto;line-height:12.6pt;text-autospace:
    none'><span style='mso-bidi-font-size:12.0pt'>Patient Safety Department
    Novartis Consulting AG - Saudi Arabia:</span><o:p></o:p></p>
    <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;
    margin-bottom:2.0pt;margin-left:.25in;mso-add-space:auto;text-indent:-.25in;
    line-height:12.6pt;mso-list:l7 level1 lfo10;text-autospace:none'><![if !supportLists]><span
    lang=EN-GB style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span lang=EN-GB
    style='mso-bidi-font-size:12.0pt'>Toll Free Number: 8001240078</span><span
    lang=EN-GB><o:p></o:p></span></p>
    <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;
    margin-bottom:0in;margin-left:.25in;mso-add-space:auto;text-indent:-.25in;
    line-height:12.6pt;mso-list:l7 level1 lfo10;text-autospace:none'><![if !supportLists]><span
    lang=EN-GB style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span lang=EN-GB
    style='mso-bidi-font-size:12.0pt'>Phone: +966112658100</span><span
    lang=EN-GB><o:p></o:p></span></p>
    <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;
    margin-bottom:0in;margin-left:.25in;mso-add-space:auto;text-indent:-.25in;
    line-height:12.6pt;mso-list:l7 level1 lfo10;text-autospace:none'><![if !supportLists]><span
    lang=EN-GB style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span lang=EN-GB
    style='mso-bidi-font-size:12.0pt'>Fax: +966112658107</span><span
    lang=EN-GB><o:p></o:p></span></p>
    <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;
    margin-bottom:0in;margin-left:.25in;mso-add-space:auto;text-indent:-.25in;
    line-height:normal;mso-list:l7 level1 lfo10;text-autospace:none'><![if !supportLists]><span
    lang=EN-GB style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span lang=EN-GB
    style='mso-bidi-font-size:12.0pt'>Email:&nbsp;adverse.events@novartis.com</span><span
    lang=EN-GB><o:p></o:p></span></p>
    <p class=MsoNormal><span style='font-family:"Arial Unicode MS",serif;
    mso-fareast-font-family:"Arial Unicode MS";mso-bidi-font-family:"Arial Unicode MS"'><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap anchorx="margin"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td style="vertical-align:top"><img width="578" height="146" alt="Text Box:  NPC contact information Saudi Arabia:

o	The National Pharmacovigilance Centre (NPC):
o	SFDA Call Center: 19999
o	E-mail: npc.drug@sfda.gov.sa
o	Website ade.sfda.gov.sa

" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.gif" /></td></tr><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td style="vertical-align:top"><img width="578" height="125" alt="Text Box: Patient Safety Department Novartis Consulting AG - Saudi Arabia:
o	Toll Free Number: 8001240078
o	Phone: +966112658100
o	Fax: +966112658107
o	Email: adverse.events@novartis.com

" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC states</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:shape
 id="Text_x0020_Box_x0020_15" o:spid="_x0000_s1027" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:0;margin-top:3.5pt;
 width:429pt;height:23.25pt;text-indent:0;z-index:251660288;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:margin;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:margin;mso-height-relative:margin;v-text-anchor:top'
 o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" fillcolor="window" strokeweight=".5pt">
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoListParagraph style='margin-bottom:0in;mso-margin-bottom-alt:
    12.0pt;mso-margin-top-alt:0in;mso-add-space:auto;text-indent:-.25in;
    line-height:normal;mso-list:l8 level1 lfo9;mso-layout-grid-align:none;
    text-autospace:none'><![if !supportLists]><span lang=EN-GB><span
    style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span lang=EN-GB
    style='font-family:"Arial Unicode MS",serif;mso-fareast-font-family:"Arial Unicode MS";
    mso-bidi-font-family:"Arial Unicode MS";color:black'>Please contact the
    relevant competent authority. <o:p></o:p></span></p>
    <p class=Default><span style='font-family:"Arial Unicode MS",serif;
    mso-fareast-font-family:"Arial Unicode MS";mso-bidi-font-family:"Arial Unicode MS"'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoNormal><span style='font-family:"Arial Unicode MS",serif;
    mso-fareast-font-family:"Arial Unicode MS";mso-bidi-font-family:"Arial Unicode MS"'><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap anchorx="margin"/>
</v:shape><![endif]--><img width="578" height="37" alt="Text Box: -	Please contact the relevant competent authority. 


" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.gif" />&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton, label or blister, after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in the original package in order to protect from moisture. Do not store above 30 &deg;C</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is rosuvastatin.<strong> </strong>Each film-coated tablet contains 10 mg of rosuvastatin (as rosuvastatin calcium).<strong>&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p>Each film-coated tablet contains 20 mg of rosuvastatin (as rosuvastatin calcium).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>&nbsp;</p><p>Tablet contents:</p><p>&nbsp;</p><p>Lactose, Silica, Colloidal Anhydrous, Silicified Microcrystalline Cellulose, Maize Starch, Talc, Sodium Stearyl Fumarate</p><p>&nbsp;</p><p>Tablet coat:</p><p>Hypromellose, Mannitol E421, Macrogol 6000, Talc, Titanium dioxide E 171, Ferric oxide, yellow E 172, Ferric oxide, red E 172</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10 mg film-coated tablets:
Brown, round, film-coated tablets with “RSV 10” debossed on one side.

20 mg film-coated tablets:
Brown, round, film-coated tablets with “RSV 20” debossed on one side.

The film-coated tablets are packed in OPA/Alu/PVC/Alu blisters.
Pack sizes:
30 film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder:</p><p>Sandoz GmbH</p><p>Biochemiestrasse 10, Kundl, Austria</p><p>Manufacturer:</p><p>Lek Pharmaceuticals d.d.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                September 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي روكسارديو إلى فئة من الأدوية تسمى ستاتينات (مثبطات مختزلة HMG-CoA).</p><p dir="RTL">&nbsp;</p><p dir="RTL">وُصف لك روكسارديو للأسباب التالية:</p><p dir="RTL">&middot;&nbsp; &nbsp;تعاني من <strong>ارتفاع مستوى الكولسترول.</strong> وهذا يعني أنك <strong>مُعرض لخطر الإصابة بنوبة قلبية أو سكتة دماغية</strong>. يُستخدم روكسارديو لدى البالغين والمراهقين والأطفال الذين تبلغ أعمارهم 6 سنوات أو أكثر لعلاج ارتفاع الكولسترول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لقد نُصحت بتناول ستاتين، لأن تغيير نظامك الغذائي وممارسة المزيد من التمارين الرياضية لم يكن كافيًا لتصحيح مستويات الكوليسترول لديك. يجب عليك الاستمرار في اتباع نظامك الغذائي الذي يقلل من الكولسترول لديك وممارسة الرياضة أثناء تناولك&nbsp;روكسارديو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أو</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp; &nbsp;لديك عوامل أخرى تزيد من خطر إصابتك بنوبة قلبية أو سكتة دماغية أو مشكلات صحية ذات صلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن تحدث النوبة القلبية والسكتة الدماغية وغيرها من المشكلات بسبب مرض يُسمّى تصلّب الشرايين. يرجع تصلّب الشرايين إلى تراكم الرواسب الدهنية في شرايينك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لماذا من المهم الاستمرار في تناول روكسارديو ؟</strong></p><p dir="RTL">يُستخدم روكسارديو لتصحيح مستويات المواد الدهنية في الدم التي تُسمّى الدهون، وأكثرها شيوعًا هو الكولسترول.</p><p dir="RTL">توجد أنواع مختلفة من الكوليسترول في الدم - الكوليسترول &quot;الضار&quot; (كوليسترول البروتين الدهني منخفض الكثافة، أو LDL-C) والكوليسترول &quot;النافع&quot; (كوليسترول البروتين الدهني عالي الكثافة، أو HDL-C).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp; &nbsp;يمكن أن يقلل روكسارديو من الكوليسترول &quot;الضار&quot; ويزيد من الكوليسترول &quot;النافع&quot;.</p><p dir="RTL">&middot;&nbsp; &nbsp;وهو يعمل من خلال المساعدة في منع إنتاج جسمك للكولسترول &quot;الضار&quot; ويحسّن من قدرة جسمك على إزالته من دمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بالنسبة لمعظم الأشخاص، لا يؤثر ارتفاع الكولسترول على ما يشعرون به لأنه لا يتسبّب في أي أعراض. ومع ذلك، إذا تُرك بدون علاج، فقد تتراكم الرواسب الدهنية في جدران الأوعية الدموية ممّا يتسبب في ضيقها.</p><p dir="RTL">في بعض الأحيان، يمكن أن تصاب هذه الأوعية الدموية الضيقة بالانسداد والذي يمكن أن يقطع إمداد الدم إلى القلب أو الدماغ ممّا يؤدي إلى حدوث نوبة قلبية أو سكتة دماغية. إذا صحّحت مستويات الكوليسترول لديك، فيمكنك تقليل خطر إصابتك بنوبة قلبية أو سكتة دماغية. من خلال خفض مستويات الكوليسترول لديك، يمكنك تقليل خطر إصابتك بنوبة قلبية أو سكتة دماغية أو مشكلات صحية ذات صلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتاج إلى <strong>الاستمرار في تناول </strong>روكسارديو، حتى إذا وصل مستوى الكوليسترول لديك إلى المستوى الصحيح، <strong>لأنه يمنع مستويات الكوليسترول لديك من الارتفاع مرة أخرى </strong>والتسبب في تراكم الرواسب الدهنية. ومع ذلك، يجب عليك التوقف إذا أخبرك طبيبك بذلك، أو إذا أصبحتِ حاملًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول روكسارديو </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك <strong>حساسية تجاه روزوفاستاتين</strong> أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ <strong>حاملًا</strong> أو <strong>تُرضعين رضاعة طبيعية. </strong>إذا أصبحتِ حاملًا أثناء تناول روكسارديو، <strong>فتوقفي عن تناوله على الفور </strong>وأخبري طبيبكِ. يجب على النساء تجنب حدوث الحمل أثناء تناول روكسارديو باستخدام وسائل منع حمل مناسبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>أمراض الكبد. </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>مشكلات خطيرة في الكلى.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>أوجاع أو آلام عضلية متكررة أو غير مبررة</strong> (اعتلال عضلي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تتناول توليفة من عقاقير سوفوسبوفير/فلباتاسفير/فوكسيلابريفير </strong>(تُستخدم لعلاج العدوى الفيروسية للكبد التي تُسمّى التهاب الكبد الوبائي ج).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول دواءًا يُسمّى <strong>سيكلوسبورين</strong> (يُستخدم، على سبيل المثال، بعد عمليات زرع الأعضاء).</p><p dir="RTL">روكسارديو روكسارديو</p><p dir="RTL">إذا كان أي ممّا سبق ينطبق عليك (أو كان يراودك شك بشأنه)، <strong>فيُرجى العودة ومراجعة طبيبك.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بالإضافة إلى ذلك، لا تتناول جرعة 40 ملغ من روكسارديو (أعلى جرعة):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من <strong>أي أوجاع أو آلام عضلية متكررة أو غير مبررة</strong> (اعتلال عضلي)، أو لديك تاريخ شخصي أو عائلي من المشكلات العضلية، أو تاريخ سابق من المشكلات العضلية عند أخذ أدوية أخرى خافضة للكوليسترول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>مشكلات متوسطة في الكلى</strong> (إذا كان يراودك شك بشأن ذلك، فيُرجى سؤال طبيبك).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت<strong> الغدة الدرقية</strong> لديك لا تعمل بصورة سليمة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت <strong>تشرب كميات كبيرة من الكحول بانتظام.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت <strong>تأخذ أدوية أخرى تُسمى الفيبرات</strong> لخفض الكولسترول لديك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا <strong>كنت من أصل آسيوي</strong> - (ياباني أو صيني أو فلبيني أو فتنامي أو كوري أو هندي).</p><p dir="RTL">إذا كان أي ممّا سبق ينطبق عليك (أو كان يراودك شك بشأنه)، <strong>فيُرجى العودة ومراجعة طبيبك.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول <strong>روكسارديو:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>مشكلات في كليتيك.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>مشكلات في كبدك.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني<strong> من فشل تنفسي شديد.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من <strong>أي أوجاع أو آلام عضلية متكررة أو غير مبررة</strong> (اعتلال عضلي)، أو لديك تاريخ شخصي أو عائلي من المشكلات العضلية، أو تاريخ سابق من المشكلات العضلية عند أخذ أدوية أخرى خافضة للكوليسترول. أخبر طبيبك على الفور إذا كنت تعاني من أوجاع أو آلام غير مبررة في العضلات خاصةً إذا كنت تشعر بتوعك أو مصابًا بالحمّى. أخبر طبيبك أو الصيدلي أيضًا إذا كنت تعاني من ضعف مستمر في العضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت <strong>تشرب كميات كبيرة من الكحول بانتظام.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت<strong> الغدة الدرقية</strong> لديك لا تعمل بصورة سليمة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تأخذ<strong> أدوية أخرى تُسمى الفيبرات</strong> لخفض الكولسترول لديك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تأخذ <strong>أدوية تُستخدم لعلاج عدوى فيروس نقص المناعة البشرية (</strong><strong>HIV</strong><strong>) </strong>(مثل ريتونافير مع لوبينافير، أتازانافير و/أو تيبرانافير)، فيُرجى الاطّلاع على الأدوية الأخرى وروكسارديو.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تأخذ أو أخذت في الأيام السبعة الماضية دواءً يُسمى حمض الفوسيديك (دواء لعلاج العدوى البكتيرية) عن طريق الفم أو الحقن. يمكن أن يؤدي الجمع بين حمض الفوسيديك وروزوفاستاتين إلى مشكلات خطيرة في العضلات (انحلال&nbsp;الربيدات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان<strong> عمرك يزيد عن 70 عامًا </strong>(حيث يحتاج طبيبك إلى اختيار جرعة البداية الصحيحة من روكسارديو لتناسبك).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا <strong>كنت من أصل آسيوي</strong> - أي ياباني أو صيني أو فلبيني أو فتنامي أو كوري أو هندي. يحتاج طبيبك إلى اختيار جرعة البداية الصحيحة من روكسارديو لتناسبك.</p><p dir="RTL">&middot;<strong> إذا كنت قد أصبت من قبل بطفح جلدي شديد أو تقشر في الجلد، أو بثور أو قرح في الفم أو كليهما بعد أخذ روزوفاستاتين أو أدوية أخرى ذات صلة.</strong><strong> </strong>أُبلغ عن ردود فعل جلدية خطيرة بما في ذلك متلازمة ستيفنس جونسون ورد فعل للعقار المترافق مع فرط اليوزينيّات والأعراض الجهازية (DRESS) مع العلاج بروزوفاستاتين. توقف عن استعمال روكسارديو واطلب الرعاية الطبية على الفور إذا لاحظت أيًا من الأعراض الموضحة في القسم 4.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كان عمر المريض أقل من 6 سنوات:</strong> يجب عدم إعطاء روكسارديو للأطفال الذين تقل أعمارهم عن 6 سنوات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كان عمر المريض أقل من 18 سنة:</strong> لا يُعد روكسارديو 40 ملغ مناسبًا للاستخدام لدى الأطفال والمراهقين دون سن 18 سنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا انطبق عليك أي ممّا سبق (أو إذا لم تكن متأكدًا):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا تتناول روكسارديو 40 ملغ (أعلى جرعة) واستشر طبيبك أو الصيدلي قبل أن تبدأ بالفعل في تناول أي جرعة من</strong><strong>&nbsp;</strong><strong>روكسارديو.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لدى عدد قليل من الأشخاص، يمكن أن تؤثر الستاتينات على الكبد. يُحدّد ذلك من خلال اختبار بسيط يكشف عن المستويات المرتفعة من إنزيمات الكبد في الدم. لهذا السبب، سيُجري طبيبك عادةً اختبار الدم هذا (اختبار وظائف الكبد) قبل العلاج بدواء روكسارديو وأثناء العلاج به.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أثناء تناول هذا الدواء، سيراقبك طبيبك عن كثب إذا كنت مصابًا بالسكري أو معرّضًا لخطر الإصابة به. من المحتمل أن تكون معرّضًا لخطر الإصابة بمرض السكري إذا كنت تعاني من ارتفاع مستويات السكر والدهون في دمك، وزيادة الوزن وارتفاع ضغط الدم لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وروكسارديو </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو إذا تناولت مؤخرًا، أو قد تتناول أية أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت بحاجة إلى أخذ حمض الفوسيديك عن طريق الفم لعلاج عدوى بكتيرية، فستحتاج إلى التوقف مؤقتًا عن استخدام هذا الدواء. سيخبرك طبيبك متى يكون من الآمن إعادة بدء تناول روكسارديو. نادرًا ما يؤدي تناول عقار روكسارديو مع حمض الفوسيديك إلى ضعف في العضلات أو إيلامها أو ألمها (انحلال الربيدات). اطّلع على المزيد من المعلومات حول انحلال الربيدات في القسم 4.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تأخذ أيًا ممّا يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>سيكلوسبورين</strong> (يُستخدم، على سبيل المثال، بعد عمليات زرع الأعضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>وارفارين أو كلوبيدوغريل </strong>أو أي دواء آخر يُستخدم لترقيق الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الفيبرات وغيرها من المنتجات الخافضة للدهون</strong> (مثل جيمفيبروزيل وفينوفيبرات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أي دواء آخر يُستخدم لخفض الكولسترول</strong> (مثل إيزيتيمبي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>علاجات عسر الهضم</strong> (تُستخدم لتحييد الحمض في معدتك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إريثرومايسين </strong>(مضاد حيوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>موانع الحمل الفموية</strong> (الحبوب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>العلاج بالهرمونات البديلة<u> </u></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ريجورافينيب </strong>(يُستخدم لعلاج السرطان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>دارولوتاميد</strong> (يُستخدم لعلاج السرطان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي من <strong>الأدوية التالية المستخدمة لعلاج العدوى الفيروسية،</strong> بما في ذلك عدوى فيروس نقص المناعة البشرية أو التهاب الكبد الوبائي ج، بمفردها أو في توليفة (يُرجى الاطّلاع على التحذيرات والاحتياطات): ريتونافير، لوبينافير، أتازانافير، سوفوسبوفير، فوكسيلابريفير، اومبيتاسفير، باريتابريفير، دازابوفير، فيلباتاسفير، جرازوبرييفير، الباسفير، غليكابريفير، بيبرنتاسفير</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن تتغير آثار هذه الأدوية بواسطة روكسارديو أو يمكن أن تغير آثار روكسارديو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>روكسارديو مع الطعام والشراب</strong></p><p dir="RTL">يمكنك تناول روكسارديو مع الطعام أو بدونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملاً أو ترضعين طبيعيًا، أو تعتقدين أنكِ حامل أو تخططين لإنجاب طفل، فاطلبي نصيحة طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تتناولي روكسارديو </strong>إذا كنتِ حاملًا أو تُرضعين رضاعة طبيعية. إذا أصبحتِ حاملًا أثناء تناول روكسارديو، <strong>فتوقفي عن تناوله على الفور </strong>وأخبري طبيبكِ. يجب على النساء تجنب حدوث الحمل أثناء تناول روكسارديو باستخدام وسائل منع حمل مناسبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستعمال الآلات</strong></p><p dir="RTL">يمكن لمعظم الأشخاص قيادة سيارة وتشغيل الآلات أثناء تناول روكسارديو - لن يؤثر ذلك على قدرتهم. ومع ذلك، يشعر بعض الأشخاص بالدوار أثناء العلاج بدواء روكسارديو. إذا شعرت بالدوار، فاستشر طبيبك قبل محاولة القيادة أو استعمال الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي روكسارديو على اللاكتوز والصوديوم</strong></p><p dir="RTL">إذا أخبرك طبيبك بأنك لا تتحمل بعض السكريات، فاتصل به قبل تناول هذا الدواء.</p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول من الصوديوم (23 ملغ) لكل قرص مغلف، أي أنه &quot;خالٍ من الصوديوم&quot; بصورة أساسية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك أو الصيدلي. يجب استشارة طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعات المعتادة لدى البالغين</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت تتناول روكسارديو لعلاج ارتفاع الكولسترول:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جرعة البداية</strong></p><p dir="RTL">يجب أن يبدأ علاجك بدواء روكسارديو بجرعة <strong>5 ملغ أو 10 ملغ</strong>، حتى إذا كنت قد تناولت جرعة أعلى من ستاتين مختلف من قبل. سيعتمد اختيار جرعة البداية الخاصة بك على:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستوى الكوليسترول لديك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستوى خطر تعرضك لنوبة قلبية أو سكتة دماغية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ما إذا كان لديك عامل قد يجعلك أكثر حساسية للآثار الجانبية المحتملة.</p><p dir="RTL">يُرجى استشارة طبيبك أو الصيدلي بشأن جرعة البداية التي تناسبك من عقار روكسارديو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يقرر طبيبك إعطاؤك أقل جرعة (5 ملغ) إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت من أصل آسيوي (ياباني أو صيني أو فلبيني أو فتنامي أو كوري أو هندي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان عمرك أكثر من 70 عامًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشكلات متوسطة في الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت معرّضًا لخطر الإصابة بأوجاع وآلام في العضلات (اعتلال عضلي).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>زيادة الجرعة والحد الأقصى للجرعة اليومية</strong></p><p dir="RTL">قد يقرر طبيبك زيادة جرعتك. وذلك حتى تتناول الكمية المناسبة لك من روكسارديو. إذا بدأت بجرعة 5 ملغ، فقد يقرر طبيبك مضاعفة ذلك إلى 10 ملغ، ثم إلى 20 ملغ ثم إلى 40 ملغ إذا لزم الأمر. إذا بدأت بجرعة 10 ملغ، فقد يقرر طبيبك مضاعفة ذلك إلى 20 ملغ، ثم إلى 40 ملغ إذا لزم الأمر. ستكون هناك فجوة مدتها أربعة أسابيع بين كل تعديل يُجرى على الجرعة.</p><p dir="RTL">تبلغ الجرعة اليومية القصوى من روكسارديو 40 ملغ. وهو مخصص فقط للمرضى الذين يعانون من ارتفاع مستويات الكوليسترول وارتفاع خطر الإصابة بنوبات قلبية أو سكتة دماغية، والذين لا تنخفض مستويات الكوليسترول لديهم بقدر كافٍ عند تناول جرعة 20 ملغ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت تتناول روكسارديو لتقليل خطر الإصابة بنوبة قلبية أو سكتة دماغية أو مشكلات صحية ذات صلة:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تبلغ الجرعة الموصى بها 20 ملغ يوميًا. ومع ذلك، قد يقرر طبيبك استخدام جرعة أقل إذا كان لديك أي من هذه العوامل المذكورة&nbsp;أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام لدى الأطفال والمراهقين الذين تتراوح أعمارهم بين 6 إلى 17 عامًا</strong></p><p dir="RTL">تبلغ جرعة البداية المعتادة 5 ملغ. قد يزيد طبيبك جرعتك لمعرفة الكمية الصحيحة المناسبة لك من روكسارديو. تبلغ الجرعة اليومية القصوى من روكسارديو 10 ملغ للأطفال الذين تتراوح أعمارهم بين 6 و9 سنوات و20 ملغ للأطفال الذين تتراوح أعمارهم بين 10 و17 سنة. تناول جرعتك مرة واحدة يوميًا. يجب <strong>ألّا </strong>يستخدم الأطفال قرص روكسارديو<strong> 40 ملغ</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول الأقراص الخاصة بك</strong></p><p dir="RTL">ابتلع كل قرص كامل مع شربة ماء.</p><p dir="RTL">تناول روكسارديو مرة واحدة يوميًا. يمكنك تناوله في أي وقت من اليوم مع الطعام أو بدونه.</p><p dir="RTL">حاول تناول القرص في الوقت نفسه كل يوم لمساعدتك على تذكره.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>فحوصات الكوليسترول المنتظمة</strong></p><p dir="RTL">من المهم العودة إلى طبيبك لإجراء فحوصات الكوليسترول المنتظمة للتأكد من وصول الكوليسترول لديك إلى المستوى الصحيح وبقائه على ذلك.</p><p dir="RTL">قد قرر طبيبك زيادة جرعتك لتتناول الكمية المناسبة لك من روكسارديو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولتَ جرعة من روكسارديو أكبر مما يجب</strong></p><p dir="RTL">اتصل بطبيبك أو أقرب مستشفى للحصول على المشورة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا ذهبت إلى المستشفى أو تلقيت علاجًا لحالة مرضية أخرى، فأخبر الفريق الطبي بأنك تتناول روكسارديو.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا نسيت تناول روكسارديو </strong></p><p dir="RTL">لا تقلق، فقط تناول جرعتك المقررة التالية في الوقت الصحيح. لا تأخذ جرعة مزدوجة لتعويض جرعة فائتة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول روكسارديو </strong></p><p dir="RTL">تحدث إلى طبيبك إذا كنت ترغب في التوقف عن تناول روكسارديو. قد تزيد مستويات الكوليسترول لديك مرة أخرى إذا توقفت عن تناول روكسارديو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية بخصوص استعمال هذا الدواء، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">من المهم أن تكون على دراية بطبيعة هذه الآثار الجانبية. وعادةً ما تكون خفيفة وتختفي بعد فترة قصيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توقف عن تناول روكسارديو واطلب المساعدة الطبية على الفور</strong> إذا كنت تعاني من أي من ردود الفعل التحسسية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس، مصحوبة أو بدون تورم في الوجه والشفتين واللسان و / أو الحلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورمًا في الوجه والشفتين واللسان والحلق أو أيّ من ذلك، والذي قد يسبب صعوبة في البلع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة شديدة في الجلد (مصحوبة بكتل بارزة)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أيضًا، توقف عن تناول روكسارديو وتحدث إلى طبيبك على الفور إذا كنت تعاني من: </strong></p><ul><li dir="RTL"><strong>أي أوجاع أو آلام غير معتادة </strong>في عضلاتك تستمر لفترة أطول ممّا تتوقع. تعتبر أعراض العضلات أكثر شيوعًا لدى الأطفال والمراهقين مقارنة بالبالغين. كما هو الحال مع الستاتينات الأخرى، عانى عدد قليل جدًا من الأشخاص من آثار عضلية غير مرغوبة ونادرًا ما أصبحت هذه الآثار تلفًا عضليًا قد يكون مهددًا للحياة يُعرف باسم<em> انحلال الربيدات.</em></li><li dir="RTL">متلازمة مرض شبيه بالذئبة الحمراء (بما في ذلك الطفح الجلدي واضطرابات المفاصل والتأثيرات على خلايا الدم)</li><li dir="RTL">تمزق العضلات</li><li dir="RTL">بقع حمراء غير بارزة تشبه علامة التصويب أو دائرية على الجسم، غالبًا مع بثور بمنتصفها، وتقشر الجلد، وقرح الفم والحلق والأنف والأعضاء التناسلية والعينين. يمكن أن يسبق الطفح الجلدي الخطير هذا الحمّى وأعراض تشبه أعراض الإنفلونزا (متلازمة ستيفنز جونسون).</li><li dir="RTL">طفح جلدي واسع الانتشار، وارتفاع درجة الحرارة، وتضخم العقد الليمفاوية (متلازمة DRESS أو متلازمة فرط الحساسية للعقار).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية</strong> <strong>الشائعة</strong> (قد تؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في كمية البروتين في البول - عادةً ما يعود هذا إلى طبيعته من تلقاء نفسه دون الاضطرار إلى التوقف عن تناول أقراص روكسارديو (فقط روكسارديو 40 ملغ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكري - تزداد احتمالية حدوثه إذا كنت تعاني من ارتفاع مستويات السكر والدهون في دمك، وتعاني من زيادة الوزن وارتفاع ضغط الدم لديك. سيراقبك طبيبك أثناء تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة</strong> (قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أو حكة أو ردود فعل جلدية أخرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في كمية البروتين في البول - عادةً ما يعود هذا إلى طبيعته من تلقاء نفسه دون الاضطرار إلى التوقف عن تناول أقراص روكسارديو (فقط روكسارديو 5 ملغ، و 10 ملغ، و20 ملغ).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة</strong><strong><em> </em></strong>(قد تؤثر على ما يصل إلى شخص واحد من كل 1,000 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي شديد - تشمل العلامات تورم الوجه والشفتين واللسان والحلق أو أيّ من ذلك، وصعوبة في البلع والتنفس، وحكة شديدة في الجلد (مصحوبة بكتل بارزة). <strong>إذا كنت تعتقد أنك تعاني من رد فعل تحسسي، فتوقف عن تناول روكسارديو واطلب المساعدة الطبية على الفور</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف العضلات لدى البالغين - كإجراء احترازي، <strong>توقف عن تناول روكسارديو وتحدث إلى طبيبك على الفور إذا كنت تعاني من أي أوجاع أو آلام غير معتادة</strong> في عضلاتك تستمر لفترة أطول من المتوقع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد في المعدة (التهاب البنكرياس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في إنزيمات الكبد في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كدمات ونزيف غير معتادين بسبب انخفاض مستوى الصفائح الدموية.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>الآثار الجانبية النادرة جدًا </strong>(قد تؤثر على ما يصل إلى شخص واحد من كل 10,000 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان (اصفرار الجلد والعينين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد (كبد ملتهب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آثار دم في البول لديك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف في أعصاب ساقيك وذراعيك (مثل الخدر)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الذاكرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التثدي (تضخم الثدي لدى الرجال).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير معروفة التكرارية (</strong>لا يمكن تقدير تكرارية حدوثها من البيانات المتوفرة):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال (براز رخو)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في النفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وذمة (تورم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات النوم، بما في ذلك الأرق والكوابيس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات جنسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في التنفس بما في ذلك السعال المستمر و/أو ضيق التنفس أو الحمّى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الأوتار، والتي تكون معقدة أحيانًا بسبب التمزق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف مستمر في العضلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للإبلاغ عن أيّ أثر جانبي (آثار جانبية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-GB><span style='mso-element:field-begin;mso-field-lock:yes'></span></span><span
dir=LTR></span><span dir=LTR></span><span lang=EN-GB dir=LTR><span dir=LTR></span><span
dir=LTR></span><span style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_1" o:spid="_x0000_s1028"
 type="#_x0000_t202" style='width:450.45pt;height:127.75pt;visibility:visible;
 mso-left-percent:-10001;mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' strokeweight=".5pt">
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoPlainText dir=RTL style='text-align:right;direction:rtl;
    unicode-bidi:embed'><span dir=LTR style='mso-bidi-font-size:10.0pt;
    mso-fareast-font-family:Arial'><span style='mso-spacerun:yes'> </span></span><span
    lang=AR-SA style='mso-bidi-font-size:10.0pt;mso-fareast-font-family:Arial'>معلومات
    الاتصال بشركة </span><span dir=LTR style='mso-bidi-font-size:10.0pt;
    mso-fareast-font-family:Arial'>NPC</span><span dir=RTL></span><span
    lang=AR-SA style='mso-bidi-font-size:10.0pt;mso-fareast-font-family:Arial'><span
    dir=RTL></span> في المملكة العربية السعودية:</span><span dir=LTR><o:p></o:p></span></p>
    <p class=MsoPlainText dir=RTL style='text-align:right;direction:rtl;
    unicode-bidi:embed'><span dir=LTR><o:p>&nbsp;</o:p></span></p>
    <p class=MsoPlainText dir=RTL style='margin-top:12.0pt;margin-right:.3in;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:right;
    text-indent:-.3in;page-break-after:avoid;mso-list:l1 level1 lfo11;
    tab-stops:list .3in left 113.4pt;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='mso-bidi-font-size:10.0pt;mso-fareast-font-family:Arial'>المركز
    الوطني للتيقظ والسلامة الدوائية (</span><span dir=LTR style='mso-bidi-font-size:
    10.0pt;mso-fareast-font-family:Arial'>NPC</span><span dir=RTL></span><span
    lang=AR-SA style='mso-bidi-font-size:10.0pt;mso-fareast-font-family:Arial'><span
    dir=RTL></span>):</span><span dir=LTR><o:p></o:p></span></p>
    <p class=MsoPlainText dir=RTL style='margin-top:12.0pt;margin-right:.3in;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:right;
    text-indent:-.3in;page-break-after:avoid;mso-list:l1 level1 lfo11;
    tab-stops:list .3in left 113.4pt;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='mso-bidi-font-size:10.0pt;mso-fareast-font-family:Arial'>مركز اتصال
    الهيئة العامة للغذاء والدواء: 19999</span><span lang=AR-SA
    style='font-size:10.5pt;mso-ansi-font-size:10.0pt'><o:p></o:p></span></p>
    <p class=MsoPlainText dir=RTL style='margin-top:12.0pt;margin-right:.3in;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:right;
    text-indent:-.3in;page-break-after:avoid;mso-list:l1 level1 lfo11;
    tab-stops:list .3in left 113.4pt;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    lang=PT-BR style='font-family:"Courier New";mso-fareast-font-family:"Courier New";
    mso-ansi-language:PT-BR'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='mso-bidi-font-size:10.0pt;mso-fareast-font-family:Arial;mso-ansi-language:
    PT-BR'>البريد الإلكتروني: </span><a href="mailto:npc.drug@sfda.gov.sa"><span
    lang=PT-BR dir=LTR style='mso-bidi-font-size:10.0pt;mso-fareast-font-family:
    Arial;color:blue;mso-ansi-language:PT-BR'>npc.drug@sfda.gov.sa</span></a><span
    lang=PT-BR dir=LTR style='mso-ansi-language:PT-BR'><o:p></o:p></span></p>
    <p class=MsoPlainText dir=RTL style='margin-top:12.0pt;margin-right:.3in;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:right;
    text-indent:-.3in;page-break-after:avoid;mso-list:l1 level1 lfo11;
    tab-stops:list .3in left 113.4pt;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='mso-bidi-font-size:10.0pt;mso-fareast-font-family:Arial'>الموقع
    الإلكتروني </span><span dir=LTR style='mso-bidi-font-size:10.0pt;
    mso-fareast-font-family:Arial'>ade.sfda.gov.sa</span><span dir=LTR><o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
    unicode-bidi:embed'><span dir=LTR style='font-family:"Arial",sans-serif;
    mso-fareast-font-family:"Arial Unicode MS"'><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="606" height="177" alt="Text Box:  معلومات الاتصال بشركة NPC في المملكة العربية السعودية:

o	المركز الوطني للتيقظ والسلامة الدوائية (NPC):
o	مركز اتصال الهيئة العامة للغذاء والدواء: 19999
o	البريد الإلكتروني: npc.drug@sfda.gov.sa
o	الموقع الإلكتروني ade.sfda.gov.sa

" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-GB dir=LTR><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:450.45pt;
 height:127.75pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-family:"Arial",sans-serif;mso-fareast-font-family:"Arial Unicode MS";
mso-no-proof:yes'><span style='mso-element:field-begin;mso-field-lock:yes'></span></span><span
dir=LTR></span><span dir=LTR></span><span dir=LTR style='font-family:"Arial",sans-serif;
mso-fareast-font-family:"Arial Unicode MS";mso-no-proof:yes'><span dir=LTR></span><span
dir=LTR></span><span style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_4"
 o:spid="_x0000_s1027" type="#_x0000_t202" style='width:451.55pt;height:89.25pt;
 visibility:visible;mso-height-percent:0;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-height-percent:0;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-width-relative:margin;mso-height-relative:margin;v-text-anchor:top'
 fillcolor="window" strokeweight=".5pt">
 <v:path arrowok="t" textboxrect="0,0,21600,21600"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal dir=RTL style='margin-top:2.0pt;margin-right:0in;
    margin-bottom:2.0pt;margin-left:0in;mso-add-space:auto;text-align:right;
    line-height:12.6pt;text-autospace:none;direction:rtl;unicode-bidi:embed'><span
    lang=AR-SA style='mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;
    mso-fareast-font-family:Arial'>قسم سلامة المرضى بشركة</span><span
    lang=AR-EG style='mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;
    mso-fareast-font-family:Arial;mso-bidi-language:AR-EG'> نوفارتس كوسنلتنغ
    ايه جي</span><span lang=AR-SA style='mso-bidi-font-size:12.0pt;font-family:
    "Arial",sans-serif;mso-fareast-font-family:Arial'> - المملكة العربية
    السعودية:</span><span dir=LTR style='font-family:"Arial",sans-serif'><o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:.25in;
    margin-bottom:2.0pt;margin-left:0in;mso-add-space:auto;text-align:right;
    text-indent:-.25in;line-height:12.6pt;mso-list:l7 level1 lfo10;text-autospace:
    none;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    lang=EN-GB style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
    Arial'>الرقم المجاني: </span><span dir=LTR></span><span lang=EN-GB dir=LTR
    style='mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
    Arial'><span dir=LTR></span>8001240078</span><span lang=AR-SA
    style='font-size:10.0pt;mso-ansi-font-size:12.0pt;font-family:"Arial",sans-serif'><o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:.25in;
    margin-bottom:0in;margin-left:0in;mso-add-space:auto;text-align:right;
    text-indent:-.25in;line-height:12.6pt;mso-list:l7 level1 lfo10;text-autospace:
    none;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    lang=EN-GB style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
    Arial'>الهاتف: </span><span dir=LTR></span><span lang=EN-GB dir=LTR
    style='mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
    Arial'><span dir=LTR></span>+966112658100</span><span lang=AR-SA
    style='font-size:10.0pt;mso-ansi-font-size:12.0pt;font-family:"Arial",sans-serif'><o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:.25in;
    margin-bottom:0in;margin-left:0in;mso-add-space:auto;text-align:right;
    text-indent:-.25in;line-height:12.6pt;mso-list:l7 level1 lfo10;text-autospace:
    none;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    lang=EN-GB style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
    Arial'>فاكس: </span><span dir=LTR></span><span lang=EN-GB dir=LTR
    style='mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
    Arial'><span dir=LTR></span>+966112658107</span><span lang=AR-SA
    style='font-size:10.0pt;mso-ansi-font-size:12.0pt;font-family:"Arial",sans-serif'><o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:.25in;
    margin-bottom:0in;margin-left:0in;mso-add-space:auto;text-align:right;
    text-indent:-.25in;line-height:normal;mso-list:l7 level1 lfo10;text-autospace:
    none;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    lang=EN-GB style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
    Arial'>البريد الإلكتروني: </span><span lang=EN-GB dir=LTR style='mso-bidi-font-size:
    12.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:Arial'>adverse.events@novartis.com</span><span
    lang=EN-GB dir=LTR style='font-family:"Arial",sans-serif'><o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
    unicode-bidi:embed'><span dir=LTR style='font-family:"Arial",sans-serif;
    mso-fareast-font-family:"Arial Unicode MS"'><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none" anchorx="margin"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="608" height="125" alt="Text Box: قسم سلامة المرضى بشركة نوفارتس كوسنلتنغ ايه جي - المملكة العربية السعودية:
o	الرقم المجاني: 8001240078
o	الهاتف: +966112658100
o	فاكس: +966112658107
o	البريد الإلكتروني: adverse.events@novartis.com

" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
dir=LTR style='font-family:"Arial",sans-serif;mso-fareast-font-family:"Arial Unicode MS";
mso-no-proof:yes'><v:shape id="_x0000_i1026" type="#_x0000_t75" style='width:451.55pt;
 height:89.25pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دول مجلس التعاون الخليجي الأخرى</p><p dir="RTL"><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-GB style='font-family:"Arial",sans-serif;mso-fareast-font-family:"Arial Unicode MS";
mso-no-proof:yes'><span style='mso-element:field-begin;mso-field-lock:yes'></span></span><span
dir=LTR></span><span dir=LTR></span><span lang=EN-GB dir=LTR style='font-family:
"Arial",sans-serif;mso-fareast-font-family:"Arial Unicode MS";mso-no-proof:
yes'><span dir=LTR></span><span dir=LTR></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_15"
 o:spid="_x0000_s1026" type="#_x0000_t202" style='width:429pt;height:23.25pt;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-width-percent:0;mso-height-percent:0;
 mso-left-percent:-10001;mso-top-percent:-10001;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' fillcolor="window"
 strokeweight=".5pt">
 <v:path arrowok="t" textboxrect="0,0,21600,21600"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoListParagraph align=right dir=RTL style='margin-top:0in;
    margin-right:.5in;margin-bottom:0in;margin-left:0in;mso-add-space:auto;
    text-align:left;text-indent:-.25in;line-height:normal;mso-list:l8 level1 lfo9;
    mso-layout-grid-align:none;text-autospace:none;direction:rtl;unicode-bidi:
    embed'><![if !supportLists]><span lang=EN-GB><span style='mso-list:Ignore'>-<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
    Arial;color:black'>يُرجى التواصل مع السلطة المختصة ذات الصلة.</span><span
    dir=LTR></span><span lang=EN-GB dir=LTR style='mso-bidi-font-size:12.0pt;
    font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;color:black'><span
    dir=LTR></span><span
    style='mso-spacerun:yes'>                                                                
    </span></span><span lang=EN-GB dir=LTR style='font-family:"Arial",sans-serif;
    mso-fareast-font-family:"Arial Unicode MS";color:black'><o:p></o:p></span></p>
    <p class=Default dir=RTL style='text-align:right;direction:rtl;unicode-bidi:
    embed'><span dir=LTR style='font-family:"Arial",sans-serif;mso-fareast-font-family:
    "Arial Unicode MS"'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
    unicode-bidi:embed'><span dir=LTR style='font-family:"Arial",sans-serif;
    mso-fareast-font-family:"Arial Unicode MS"'><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none" anchorx="margin"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="578" height="37" alt="Text Box: -	يُرجى التواصل مع السلطة المختصة ذات الصلة.                                                                 


" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-GB dir=LTR style='font-family:"Arial",sans-serif;mso-fareast-font-family:
"Arial Unicode MS";mso-no-proof:yes'><v:shape id="_x0000_i1027" type="#_x0000_t75"
 style='width:429pt;height:23.25pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن رؤية ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء صلاحيته المدوَّن على العلبة الكرتونية والملصق أو الشريط بعد كلمة EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احفظها في العبوة الأصلية للحماية من الرطوبة. لا تخزنه في درجة حرارة أعلى من 30 درجة مئوية</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أية أدوية في مياه الصرف أو المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي روزوفاستاتين.</p><p dir="RTL">يحتوي كل قرص مغلف على 10 ملغ من روزوفاستاتين (مثل روزوفاستاتين الكالسيوم).<strong>&nbsp; </strong></p><p dir="RTL">يحتوي كل قرص مغلف على 20 ملغ من روزوفاستاتين (مثل روزوفاستاتين الكالسيوم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">محتويات القرص:</p><p dir="RTL">&nbsp;</p><p dir="RTL">اللاكتوز، السيليكا، الغرواني اللامائي، السليلوز البلوري الدقيق السيليكي، نشاء الذرة، التلك، ستيريل فومارات الصوديوم</p><p dir="RTL">&nbsp;</p><p dir="RTL">غلاف القرص:</p><p dir="RTL">هيبروميلوز، مانيتول E421، ماكروجول 6000، تالك، ثاني أكسيد التيتانيوم E 171، أكسيد الحديديك، أصفر E 172، أكسيد الحديديك، أحمر E 172</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><em>أقراص مغلفة 10 ملغ:</em></p><p dir="RTL">أقراص بنية، مستديرة، مغلفة ومطبوع عليها &quot;RSV 10&quot; على جانب واحد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>أقراص مغلفة 20 ملغ:</em></p><p dir="RTL">أقراص بنية، مستديرة، مغلفة ومطبوع عليها &quot;RSV 20&quot; على جانب واحد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأقراص المغلفة معبأة في شرائط بلاستيك من OPA/Alu/PVC/Alu.</p><p dir="RTL">أحجام العبوات:</p><p dir="RTL">30 قرصًا مغلفًا</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التَّسويق: </strong></p><p dir="RTL">شركة ساندوز المحدودة</p><p dir="RTL">بيوشيمي شتراسه 10، كوندل، النمسا</p><p dir="RTL"><strong>جهة التصنيع: </strong></p><p dir="RTL">شركة ليك للصناعات الدَّوائية شركة مساهمة</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            سبتمبر 2022


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Roxardio 10 mg film-coated tablets
Roxardio 20 mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Roxardio 10 mg film-coated tablets
Each film-coated tablet contains 10 mg rosuvastatin (as rosuvastatin calcium).
Excipients with known effects: Each film-coated tablet contains 52.9 mg lactose anhydrous
Roxardio 20 mg film-coated tablets
Each film-coated tablet contains 20 mg rosuvastatin (as rosuvastatin calcium).
Excipients with known effects: Each film-coated tablet contains 105.8 mg lactose anhydrous

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Roxardio 10 mg film-coated tablets
Brown, round, film-coated tablets with “RSV 10”debossed on one side.

Roxardio 20 mg film-coated tablets
Brown, round, film-coated tablets with “RSV 20”debossed on one side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Treatment of hypercholesterolaemia</strong></p><p>Adults, adolescents and children aged 6 years or older with primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate.</p><p>Homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.</p><p><strong>&nbsp;</strong></p><p><strong>Prevention of Cardiovascular Events</strong></p><p>Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event (see section 5.1), as an adjunct to correction of other risk factors.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before treatment initiation the patient should be placed on a standard cholesterol-lowering diet that should continue during treatment. The dose should be individualised according to the goal of therapy and patient response, using current consensus guidelines.</p><p>&nbsp;</p><p>Roxardio may be given at any time of day, with or without food.</p><p>&nbsp;</p><p><strong>Treatment of hypercholesterolaemia</strong></p><p>The recommended start dose is 5 or 10 mg orally once daily in both statin na&iuml;ve or patients switched from another HMG-CoA reductase inhibitor. The choice of start dose should take into account the individual patient&rsquo;s cholesterol level and future cardiovascular risk as well as the potential risk for adverse reactions (see below). A dose adjustment to the next dose level can be made after 4 weeks, if necessary (see section 5.1). In light of the increased reporting rate of adverse reactions with the 40 mg dose compared to lower doses (see section 4.8), a final titration to the maximum dose of 40 mg should only be considered in patients with severe hypercholesterolaemia at high cardiovascular risk (in particular those with familial hypercholesterolaemia), who do not achieve their treatment goal on 20 mg, and in whom routine follow-up will be performed (see section 4.4).</p><p>&nbsp;</p><p>Specialist supervision is recommended when the 40 mg dose is initiated.</p><p>&nbsp;</p><p><strong>Prevention of cardiovascular events</strong></p><p>In the cardiovascular events risk reduction study, the dose used was 20 mg daily (see section 5.1).</p><p>&nbsp;</p><p><strong>Paediatric population</strong></p><p>Paediatric use should only be carried out by specialists.</p><p>&nbsp;</p><p><u>Children and adolescents 6 to 17 years of age (Tanner Stage &lt;II-V)</u></p><p>In children and adolescents with heterozygous familial hypercholesterolaemia the usual start dose is 5 mg daily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In children 6 to 9 years of age with heterozygous familial hypercholesterolaemia, the usual dose range is 5-10 mg orally once daily. Safety and efficacy of doses greater than 10 mg have not been studied in this population.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In children 10 to 17 years of age with heterozygous familial hypercholesterolaemia, the usual dose range is 5-20 mg orally once daily. Safety and efficacy of doses greater than 20 mg have not been studied in this population.</p><p>&nbsp;</p><p>Titration should be conducted according to the individual response and tolerability in paediatric patients, as recommended by the paediatric treatment recommendations (see section 4.4). Children and adolescents should be placed on standard cholesterol lowering diet before rosuvastatin treatment initiation; this diet should be continued during rosuvastatin treatment.<br />&nbsp;</p><p>Experience in children with homozygous familial hypercholesterolaemia is limited to a small number of children aged between 8 and 17 years.</p><p><br />The 40 mg tablet is not suitable for use in paediatric patients.</p><p>&nbsp;</p><p><u>Children younger than 6 years</u></p><p>The safety and efficacy of use in children younger than 6 years has not been studied. Therefore, Roxardio is not recommended for use in children younger than 6 years.</p><p>&nbsp;</p><p><strong>Elderly</strong></p><p>A start dose of 5 mg is recommended in patients &gt;70 years (see section 4.4). No other dose adjustment is necessary in relation to age.</p><p>&nbsp;</p><p><strong>Renal impairment </strong></p><p>No dose adjustment is necessary in patients with mild to moderate renal impairment.</p><p>The recommended start dose is 5 mg in patients with moderate renal impairment (creatinine clearance &lt;60 ml/min). The 40 mg dose is contraindicated in patients with moderate renal impairment. The use of Roxardio in patients with severe renal impairment is contraindicated for all doses (see sections 4.3 and 5.2).</p><p>&nbsp;</p><p><strong>Hepatic impairment </strong></p><p>There was no increase in systemic exposure to rosuvastatin in subjects with Child-Pugh scores of 7 or below. However, increased systemic exposure has been observed in subjects with Child-Pugh scores of 8 and 9 (see section 5.2). In these patients an assessment of renal function should be considered (see section 4.4). There is no experience in subjects with Child-Pugh scores above 9. Roxardio is contraindicated in patients with active liver disease (see section 4.3).</p><p>&nbsp;</p><p><strong>Race </strong></p><p>Increased systemic exposure has been seen in Asian subjects (see sections 4.3, 4.4 and 5.2). The recommended start dose is 5 mg for patients of Asian ancestry. The 40 mg dose is contraindicated in these patients.</p><p>&nbsp;</p><p><strong>Genetic polymorphisms</strong></p><p>Specific types of genetic polymorphisms are known that can lead to increased rosuvastatin exposure (see section 5.2). For patients who are known to have such specific types of polymorphisms, a lower daily dose of Roxardio is recommended.</p><p>&nbsp;</p><p><strong>Patients with pre-disposing factors to myopathy </strong></p><p>The recommended start dose is 5 mg in patients with predisposing factors to myopathy (see section 4.4).</p><p>&nbsp;</p><p>The 40 mg dose is contraindicated in some of these patients (see section 4.3).</p><p>&nbsp;</p><p><strong>Concomitant therapy</strong></p><p>Rosuvastatin is a substrate of various transporter proteins (e.g. OATP1B1 and BCRP). The risk of myopathy (including rhabdomyolysis) is increased when rosuvastatin is administered concomitantly with certain medicinal products that may increase the plasma concentration of rosuvastatin due to interactions with these transporter proteins (e.g. ciclosporin and certain protease inhibitors including combinations of ritonavir with atazanavir, lopinavir, and/or tipranavir; see sections 4.4 and 4.5). Whenever possible, alternative medicinal products should be considered, and, if necessary, consider temporarily discontinuing Roxardio therapy. In situations where co-administration of these medicinal products with Roxardio is unavoidable, the benefit and the risk of concurrent treatment and Roxardio dosing adjustments should be carefully considered (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Roxardio is contraindicated: 
	in patients with hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
	in patients with active liver disease including unexplained, persistent elevations of serum transaminases and any serum transaminase elevation exceeding 3 x the upper limit of normal (ULN). 
	in patients with severe renal impairment (creatinine clearance <30 ml/min). 
	in patients with myopathy. 
	in patients receiving concomitant combination of sofosbuvir/velpatasvir/voxilaprevir (see section 4.5).
	in patients receiving concomitant ciclosporin. 
	during pregnancy and lactation and in women of childbearing potential not using appropriate contraceptive measures. 

The 40 mg dose is contraindicated in patients with pre-disposing factors for myopathy/rhabdomyolysis. Such factors include: 
	moderate renal impairment (creatinine clearance < 60 ml/min) 
	hypothyroidism 
	personal or family history of hereditary muscular disorders 
	previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate 
	alcohol abuse 
	situations where an increase in plasma levels may occur 
	Asian patients 
	concomitant use of fibrates. 

(see sections 4.4, 4.5 and 5.2)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Renal Effects </u></p><p>Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients treated with higher doses of rosuvastatin, in particular 40 mg, where it was transient or intermittent in most cases. Proteinuria has not been shown to be predictive of acute or progressive renal disease (see section 4.8). The reporting rate for serious renal events in post-marketing use is higher at the 40 mg dose. An assessment of renal function should be considered during routine follow-up of patients treated with a dose of 40 mg.</p><p>&nbsp;</p><p><u>Skeletal Muscle Effects </u></p><p>Effects on skeletal muscle e.g. myalgia, myopathy and, rarely, rhabdomyolysis have been reported in rosuvastatin-treated patients with all doses and in particular with doses &gt; 20 mg. Very rare cases of rhabdomyolysis have been reported with the use of ezetimibe in combination with HMG-CoA reductase inhibitors. A pharmacodynamic interaction cannot be excluded (see section 4.5) and caution should be exercised with their combined use.</p><p>As with other HMG-CoA reductase inhibitors, the reporting rate for rhabdomyolysis associated with rosuvastatin in post-marketing use is higher at the 40 mg dose.</p><p><strong>&nbsp;</strong></p><p><em>Creatine Kinase Measurement </em></p><p>Creatine Kinase (CK) should not be measured following strenuous exercise or in the presence of a plausible alternative cause of CK increase which may confound interpretation of the result. If CK levels are significantly elevated at baseline (&gt;5xULN) a confirmatory test should be carried out within 5 &ndash; 7 days. If the repeat test confirms a baseline CK &gt;5xULN, treatment should not be started.</p><p>&nbsp;</p><p><em>Before Treatment </em></p><p>Roxardio , as with other HMG-CoA reductase inhibitors, should be prescribed with caution in patients with pre-disposing factors for myopathy/rhabdomyolysis. Such factors include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; renal impairment</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypothyroidism</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; personal or family history of hereditary muscular disorders</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alcohol abuse</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; age &gt;70 years</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; situations where an increase in plasma levels may occur (see sections 4.2, 4.5 and 5.2)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; concomitant use of fibrates.</p><p><strong>&nbsp;</strong></p><p>In such patients the risk of treatment should be considered in relation to possible benefit and clinical monitoring is recommended. If CK levels are significantly elevated at baseline (&gt;5xULN) treatment should not be started.</p><p>&nbsp;</p><p><em>Whilst on Treatment </em></p><p>Patients should be asked to report inexplicable muscle pain, weakness or cramps immediately, particularly if associated with malaise or fever. CK levels should be measured in these patients. Therapy should be discontinued if CK levels are markedly elevated (&gt;5xULN) or if muscular symptoms are severe and cause daily discomfort (even if CK levels are &le; 5x ULN). If symptoms resolve and CK levels return to normal, then consideration should be given to re-introducing Roxardio or an alternative HMG-CoA reductase inhibitor at the lowest dose with close monitoring. Routine monitoring of CK levels in asymptomatic patients is not warranted. There have been very rare reports of an immune-mediated necrotising myopathy (IMNM) during or after treatment with statins, including rosuvastatin. IMNM is clinically characterized by proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment.</p><p>&nbsp;</p><p>In clinical trials there was no evidence of increased skeletal muscle effects in the small number of patients dosed with rosuvastatin and concomitant therapy. However, an increase in the incidence of myositis and myopathy has been seen in patients receiving other HMG-CoA reductase inhibitors together with fibric acid derivatives including gemfibrozil, ciclosporin, nicotinic acid, azole antifungals, protease inhibitors and macrolide antibiotics. Gemfibrozil increases the risk of myopathy when given concomitantly with some HMG-CoA reductase inhibitors. Therefore, the combination of Roxardio and gemfibrozil is not recommended. The benefit of further alterations in lipid levels by the combined use of Roxardio with fibrates or niacin should be carefully weighed against the potential risks of such combinations. The 40 mg dose is contraindicated with concomitant use of a fibrate (see sections 4.5 and 4.8).</p><p>Rosuvastatin must not be co-administered with systemic formulations of fusidic acid or within 7 days of stopping fusidic acid treatment. In patients where the use of systemic fusidic acid is considered essential, statin treatment should be discontinued throughout the duration of fusidic acid treatment. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving fusidic acid and statins in combination (see section 4.5). The patient should be advised to seek medical advice immediately if they experience any symptoms of muscle weakness, pain or tenderness.</p><p>Statin therapy may be re-introduced seven days after the last dose of fusidic acid.</p><p>In exceptional circumstances, where prolonged systemic fusidic acid is needed, e.g., for the treatment of severe infections, the need for co-administration of rosuvastatin and fusidic acid should only be considered on a case by case basis and under close medical supervision.</p><p><strong>&nbsp;</strong></p><p>Roxardio should not be used in any patient with an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders; or uncontrolled seizures).</p><p>&nbsp;</p><p><u>Severe Cutaneous Adverse Reactions</u></p><p>Severe cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS), which could be life-threatening or fatal, have been reported with rosuvastatin (see section 4.8). At the time of prescription, patients should be advised of the signs and symptoms of severe skin reactions and be closely monitored. If signs and symptoms suggestive of this reaction appear, Roxardio should be discontinued immediately and an alternative treatment should be considered.</p><p>If the patient has developed a serious reaction such as SJS or DRESS with the use of Roxardio , treatment with Roxardio must not be restarted in this patient at any time.</p><p>&nbsp;</p><p><u>Liver Effects</u></p><p>As with other HMG-CoA reductase inhibitors, Roxardio should be used with caution in patients who consume excessive quantities of alcohol and/or have a history of liver disease.</p><p>It is recommended that liver function tests be carried out prior to, and 3 months following, the initiation of treatment. Roxardio should be discontinued or the dose reduced if the level of serum transaminases is greater than 3 times the upper limit of normal. The reporting rate for serious hepatic events (consisting mainly of increased hepatic transaminases) in post-marketing use is higher at the 40 mg dose.</p><p>In patients with secondary hypercholesterolaemia caused by hypothyroidism or nephrotic syndrome, the underlying disease should be treated prior to initiating therapy with Roxardio .</p><p>&nbsp;</p><p><u>Race </u></p><p>Pharmacokinetic studies show an increase in exposure in Asian subjects compared with Caucasians (see sections 4.2, 4.3 and 5.2).</p><p><strong>&nbsp;</strong></p><p><u>Protease inhibitors </u></p><p>Increased systemic exposure to rosuvastatin has been observed in subjects receiving rosuvastatin concomitantly with various protease inhibitors in combination with ritonavir. Consideration should be given both to the benefit of lipid lowering by use of Roxardio in HIV patients receiving protease inhibitors and the potential for increased rosuvastatin plasma concentrations when initiating and up titrating Roxardio doses in patients treated with protease inhibitors. The concomitant use with certain protease inhibitors is not recommended unless the dose of Roxardio is adjusted (see sections 4.2 and 4.5).</p><p><strong>&nbsp;</strong></p><p><u>Interstitial lung disease</u></p><p>Exceptional cases of interstitial lung disease have been reported with some statins, especially with long term therapy (see section 4.8). Presenting features can include dyspnoea, non-productive cough and deterioration in general health (fatigue, weight loss and fever). If it is suspected that a patient has developed interstitial lung disease, statin therapy should be discontinued.</p><p>&nbsp;</p><p><u>Diabetes Mellitus</u></p><p>Some evidence suggests that statins as a class raise blood glucose and in some patients, at high risk of future diabetes, may produce a level of hyperglycaemia where formal diabetes care is appropriate. This risk, however, is outweighed by the reduction in vascular risk with statins and therefore should not be a reason for stopping statin treatment. Patients at risk (fasting glucose 5.6 to 6.9 mmol/L, BMI &gt; 30 kg/m<sup>2</sup>, raised triglycerides, hypertension) should be monitored both clinically and biochemically according to national guidelines.</p><p>&nbsp;</p><p>In the JUPITER study, the reported overall frequency of diabetes mellitus was 2.8% in rosuvastatin and 2.3% in placebo, mostly in patients with fasting glucose 5.6 to 6.9 mmol/L.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The evaluation of linear growth (height), weight, BMI (body mass index), and secondary characteristics of sexual maturation by Tanner staging in paediatric patients 6 to 17 years of age taking rosuvastatin is limited to a two-year period. After two years of study treatment, no effect on growth, weight, BMI or sexual maturation was detected (see section 5.1).</p><p>&nbsp;</p><p>In a clinical trial of children and adolescents receiving rosuvastatin for 52 weeks, CK elevations &gt;10xULN and muscle symptoms following exercise or increased physical activity were observed more frequently compared to observations in clinical trials in adults (see section 4.8).</p><p>&nbsp;</p><p><u>Roxardio </u><u>contains lactose and sodium</u></p><p>Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p>&nbsp;</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effect of co-administered medicinal products on rosuvastatin</u></p><p><strong>Transporter protein inhibitors:</strong> Rosuvastatin is a substrate for certain transporter proteins including the hepatic uptake transporter OATP1B1 and efflux transporter BCRP. Concomitant administration of rosuvastatin with medicinal products that are inhibitors of these transporter proteins may result in increased rosuvastatin plasma concentrations and an increased risk of myopathy (see sections 4.2, 4.4, and 4.5 Table 1).</p><p><em>&nbsp;</em></p><p><em>Ciclosporin:</em> During concomitant treatment with rosuvastatin and ciclosporin, rosuvastatin AUC values were on average 7 times higher than those observed in healthy volunteers (see Table 1). Roxardio is contraindicated in patients receiving concomitant ciclosporin (see section 4.3). Concomitant administration did not affect plasma concentrations of ciclosporin.</p><p>&nbsp;</p><p><em>Protease inhibitors</em>: Although the exact mechanism of interaction is unknown, concomitant protease inhibitor use may strongly increase rosuvastatin exposure (see Table 1). For instance, in a pharmacokinetic study, co-administration of 10 mg rosuvastatin and a combination product of two protease inhibitors (300 mg atazanavir / 100 mg ritonavir) in healthy volunteers was associated with an approximately three-fold and seven-fold increase in rosuvastatin AUC and C<sub>max</sub> respectively. The concomitant use of Roxardio and some protease inhibitor combinations may be considered after careful consideration of Roxardio dose adjustments based on the expected increase in rosuvastatin exposure (see sections 4.2, 4.4, and 4.5 Table 1).&nbsp;</p><p>&nbsp;</p><p><strong>Gemfibrozil and other lipid-lowering products:</strong> Concomitant use of rosuvastatin<strong> </strong>and gemfibrozil resulted in a 2-fold increase in rosuvastatin C<sub>max</sub> and AUC (see section 4.4).</p><p>&nbsp;</p><p>Based on data from specific interaction studies no pharmacokinetic relevant interaction with fenofibrate is expected, however a pharmacodynamic interaction may occur. Gemfibrozil, fenofibrate, other fibrates and lipid lowering doses (&gt; or equal to 1g/day) of niacin (nicotinic acid) increase the risk of myopathy when given concomitantly with HMG-CoA reductase inhibitors, probably because they can produce myopathy when given alone. The 40 mg dose is contraindicated with concomitant use of a fibrate (see sections 4.3 and 4.4). These patients should also start with the 5 mg dose.</p><p>&nbsp;</p><p><strong>Ezetimibe</strong>: Concomitant use of 10 mg rosuvastatin<strong> </strong>and 10 mg ezetimibe resulted in a 1.2-fold increase in AUC of rosuvastatin in hypercholesterolaemic subjects (Table 1). A pharmacodynamic interaction, in terms of adverse effects, between Roxardio and ezetimibe cannot be ruled out (see section 4.4).</p><p>&nbsp;</p><p><strong>Antacid</strong>: The simultaneous dosing of rosuvastatin<strong> </strong>with an antacid suspension containing aluminium and magnesium hydroxide resulted in a decrease in rosuvastatin plasma concentration of approximately 50%. This effect was mitigated when the antacid was dosed 2 hours after rosuvastatin. The clinical relevance of this interaction has not been studied.&nbsp;</p><p>&nbsp;</p><p><strong>Erythromycin</strong>: Concomitant use of rosuvastatin<strong> </strong>and erythromycin resulted in a 20% decrease in AUC and a 30% decrease in C<sub>max</sub> of rosuvastatin. This interaction may be caused by the increase in gut motility caused by erythromycin.</p><p>&nbsp;</p><p><strong>Cytochrome P450 enzymes</strong>: Results from <em>in vitro</em> and <em>in vivo</em> studies show that rosuvastatin is neither an inhibitor nor an inducer of cytochrome P450 isoenzymes. In addition, rosuvastatin is a poor substrate for these isoenzymes. Therefore, drug interactions resulting from cytochrome P450-mediated metabolism are not expected<em>. </em>No clinically relevant interactions have been observed between rosuvastatin and either fluconazole (an inhibitor of CYP2C9 and CYP3A4) or ketoconazole (an inhibitor of CYP2A6 and CYP3A4).</p><p>&nbsp;</p><p><strong>Interactions requiring rosuvastatin dose adjustments (see also Table 1):</strong><strong> </strong>When it is necessary to co-administer Roxardio with other medicinal products known to increase exposure to rosuvastatin, doses of Roxardio should be adjusted. Start with a 5 mg once daily dose of Roxardio if the expected increase in exposure (AUC) is approximately 2‑fold or higher. The maximum daily dose of Roxardio should be adjusted so that the expected rosuvastatin exposure would not likely exceed that of a 40 mg daily dose of Roxardio taken without interacting medicinal products, for example a 20 mg dose of Roxardio with gemfibrozil (1.9-fold increase), and a 10 mg dose of Roxardio with combination atazanavir/ritonavir (3.1-fold increase).</p><p>If medicinal product is observed to increase rosuvastatin AUC less than 2-fold, the starting dose need not be decreased but caution should be taken if increasing the Roxardio dose above 20 mg.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 1 Effect of co-administered medicinal products on rosuvastatin exposure (AUC; in order of decreasing magnitude) from published clinical trials</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>2-fold or greater than 2-fold increase in AUC of rosuvastatin</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Interacting drug dose regimen</strong></p></td><td style="vertical-align:top"><p>Rosuvastatin dose regimen</p></td><td style="vertical-align:top"><p><strong>Change in rosuvastatin AUC<sup>*</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Sofosbuvir/velpatasvir/voxilaprevir (400 mg-100 mg-100 mg) + Voxilaprevir (100 mg)&nbsp; once daily for 15 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>7.4-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Ciclosporin 75 mg BID to 200 mg BID, 6 months</p></td><td style="vertical-align:top"><p>10 mg OD, 10 days</p></td><td style="vertical-align:top"><p>7.1-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Darolutamide 600 mg BID, 5 days</p></td><td style="vertical-align:top"><p>5 mg, single dose</p></td><td style="vertical-align:top"><p>5.2-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Regorafenib 160 mg, OD, 14 days</p></td><td style="vertical-align:top"><p>5 mg single dose</p></td><td style="vertical-align:top"><p>3.8-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Atazanavir 300 mg/ritonavir 100 mg OD, 8 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>3.1-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Velpatasvir 100 mg OD</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>2.7-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Ombitasvir 25 mg/paritaprevir 150 mg/ Ritonavir 100 mg OD/ dasabuvir 400 mg BID, 14 days</p></td><td style="vertical-align:top"><p>5 mg, single dose</p></td><td style="vertical-align:top"><p>2.6-fold &uarr;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Grazoprevir 200 mg/elbasvir &nbsp;&nbsp;&nbsp;&nbsp; 50mg OD, 11 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>2.3-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Glecaprevir 400 mg/pibrentasvir 120 mg OD, 7 days</p></td><td style="vertical-align:top"><p>5 mg OD, 7 days</p></td><td style="vertical-align:top"><p>2.2-fold &uarr;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Lopinavir 400 mg/ritonavir 100 mg BID, 17 days</p></td><td style="vertical-align:top"><p>20 mg OD, 7 days</p></td><td style="vertical-align:top"><p>2.1-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Clopidogrel 300 mg loading, followed by 75 mg at 24 hours</p></td><td style="vertical-align:top"><p>20 mg, single dose</p></td><td style="vertical-align:top"><p>2-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Gemfibrozil 600 mg BID, 7 days</p></td><td style="vertical-align:top"><p>80 mg, single dose</p></td><td style="vertical-align:top"><p>1.9-fold &uarr;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Less than 2-fold increase in AUC of rosuvastatin</strong></p></td></tr><tr><td style="vertical-align:top"><p>Eltrombopag 75 mg OD, 5 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>1.6-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Darunavir 600 mg/ritonavir 100 mg BID, 7 days</p></td><td style="vertical-align:top"><p>10 mg OD, 7 days</p></td><td style="vertical-align:top"><p>1.5-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Tipranavir 500 mg/ritonavir 200 mg BID, 11 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>1.4-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Dronedarone 400 mg BID</p></td><td style="vertical-align:top"><p>Not available</p></td><td style="vertical-align:top"><p>1.4-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Itraconazole 200 mg OD, 5 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>1.4-fold &uarr;<sup>**</sup></p></td></tr><tr><td style="vertical-align:top"><p>Ezetimibe 10 mg OD, 14 days</p></td><td style="vertical-align:top"><p>10 mg, OD, 14 days</p></td><td style="vertical-align:top"><p>1.2-fold &uarr;<sup>**</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Decrease in AUC of rosuvastatin</strong></p></td></tr><tr><td style="vertical-align:top"><p>Erythromycin 500 mg QID, 7 days</p></td><td style="vertical-align:top"><p>80 mg, single dose</p></td><td style="vertical-align:top"><p>20% &darr;</p></td></tr><tr><td style="vertical-align:top"><p>Baicalin 50 mg TID, 14 days</p></td><td style="vertical-align:top"><p>20 mg, single dose</p></td><td style="vertical-align:top"><p>47% &darr;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*</sup>Data given as x-fold change represent a simple ratio between co-administration and rosuvastatin alone. Data given as % change represent % difference relative to rosuvastatin alone.</p><p>Increase is indicated as &ldquo;&uarr;&rdquo;, decrease as &ldquo;&darr;&rdquo;.</p><p><sup>**</sup>Several interaction studies have been performed at different rosuvastatin dosages, the table shows the most significant ratio</p><p>AUC = area under curve; OD = once daily; BID = twice daily; TID = three times daily; QID = four times daily</p></td></tr></tbody></table><p>&nbsp;</p><p>The following medical product/combinations did not have a clinically significant effect on the AUC ratio of rosuvastatin at coadministration:</p><p>Aleglitazar 0.3 mg 7 days dosing; Fenofibrate 67 mg 7 days TID dosing; Fluconazole 200mg 11 days OD dosing; Fosamprenavir 700 mg/ritonavir 100 mg 8 days BID dosing; Ketoconazole 200 mg 7 days BID dosing; Rifampin 450 mg 7 days OD dosing; Silymarin 140 mg 5 days TID dosing.</p><p>&nbsp;</p><p><u>Effect of rosuvastatin on co-administered medicinal products</u></p><p><strong>Vitamin K antagonists</strong>: As with other HMG-CoA reductase inhibitors, the initiation of treatment or dosage up-titration of Roxardio in patients treated concomitantly with vitamin K antagonists (e.g. warfarin or another coumarin anticoagulant) may result in an increase in International Normalised Ratio (INR). Discontinuation or down-titration of Roxardio may result in a decrease in INR. In such situations, appropriate monitoring of INR is desirable.</p><p>&nbsp;</p><p><strong>Oral contraceptive/hormone replacement therapy (HRT)</strong>: Concomitant use of rosuvastatin<strong> </strong>and an oral contraceptive resulted in an increase in ethinyl estradiol and norgestrel AUC of 26% and 34%, respectively. These increased plasma levels should be considered when selecting oral contraceptive doses. There are no pharmacokinetic data available in subjects taking concomitant rosuvastatin<strong> </strong>and HRT and therefore a similar effect cannot be excluded. However, the combination has been extensively used in women in clinical trials and was well tolerated.</p><p>&nbsp;</p><p><strong>Other medicinal products</strong>:</p><p>&nbsp;</p><p><strong>Digoxin:</strong> Based on data from specific interaction studies no clinically relevant interaction with digoxin is expected.</p><p>&nbsp;</p><p><strong>Fusidic Acid:</strong> The risk of myopathy including rhabdomyolysis may be increased by the concomitant administration of systemic fusidic acid with statins. The mechanism of this interaction (whether it is pharmacodynamic or pharmacokinetic, or both) is yet unknown. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving this combination.</p><p>If treatment with systemic fusidic acid is necessary, rosuvastatin treatment should be discontinued throughout the duration of the fusidic acid treatment. <strong>Also see section 4.4</strong>.</p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults. The extent of interactions in the paediatric population is not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Roxardio is contraindicated in pregnancy and lactation.</p><p>&nbsp;</p><p>Women of child bearing potential should use appropriate contraceptive measures.</p><p>&nbsp;</p><p>Since cholesterol and other products of cholesterol biosynthesis are essential for the development of the foetus, the potential risk from inhibition of HMG-CoA reductase outweighs the advantage of treatment during pregnancy. Animal studies provide limited evidence of reproductive toxicity (see section 5.3). If a patient becomes pregnant during use of this product, treatment should be discontinued immediately.</p><p>&nbsp;</p><p>Rosuvastatin is excreted in the milk of rats. There are no data with respect to excretion in milk in humans (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Studies to determine the effect of Roxardio on the ability to drive and use machines have not been conducted. However, based on its pharmacodynamic properties, Roxardio is unlikely to affect this ability. When driving vehicles or operating machines, it should be taken into account that dizziness may occur during treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse reactions seen with rosuvastatin are generally mild and transient. In controlled clinical trials, less than 4% of rosuvastatin-treated patients were withdrawn due to adverse reactions.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Based on data from clinical studies and extensive post-marketing experience, the following table presents the adverse reaction profile for rosuvastatin. Adverse reactions listed below are classified according to frequency and system organ class (SOC).</p><p>&nbsp;</p><p>The frequencies of adverse reactions are ranked according to the following convention:</p><p>&nbsp;</p><p>Very common (&ge;1/10)</p><p>Common (&ge;1/100 to &lt;1/10)</p><p>Uncommon (&ge;1/1,000 to &lt;1/100)</p><p>Rare (&ge;1/10,000 to &lt;1/1,000)</p><p>Very rare (&lt;1/10,000)</p><p>Not known (cannot be estimated from the available data)</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp; </strong></p><p><strong>Table 2 Adverse reactions based on data from clinical studies and post-marketing experience</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:657px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class&nbsp; </strong></p></td><td style="vertical-align:top"><p><strong>Common&nbsp; </strong></p></td><td style="vertical-align:top"><p><strong>Uncommon&nbsp; </strong></p></td><td style="vertical-align:top"><p><strong>Rare&nbsp; </strong></p></td><td style="vertical-align:top"><p><strong>Very rare&nbsp; </strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Blood and lymphatic system disorders&nbsp; </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombocytopenia&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Immune system disorders&nbsp; </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions including angioedema&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Endocrine disorders&nbsp; </em></p></td><td style="vertical-align:top"><p>Diabetes mellitus<sup>1</sup>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Psychiatric disorders&nbsp; </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Depression</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous system disorders&nbsp; </em></p></td><td style="vertical-align:top"><p>Headache Dizziness&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Polyneuropathy</p><p>Memory loss&nbsp;</p></td><td style="vertical-align:top"><p>Peripheral neuropathy</p><p>Sleep disturbances (including insomnia and nightmares)</p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders&nbsp; </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cough Dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal disorders&nbsp; </em></p></td><td style="vertical-align:top"><p>Constipation Nausea Abdominal pain&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pancreatitis&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p><em>Hepatobiliary disorders&nbsp; </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increased hepatic transaminases&nbsp;</p></td><td style="vertical-align:top"><p>Jaundice</p><p>Hepatitis&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Skin and subcutaneous tissue&nbsp; </em></p><p><em>disorders&nbsp; </em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pruritis&nbsp;</p><p>Rash&nbsp;</p><p>Urticaria&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Stevens- Johnson Syndrome,</p><p>Drug reaction with eosinophilia and systemic symptoms (DRESS)</p></td></tr><tr><td style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders&nbsp; </em></p></td><td style="vertical-align:top"><p>Myalgia&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myopathy (including myositis) Rhabdomyolysis</p><p>Lupus-like syndrome</p><p>Muscle rupture&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Immune-mediated necrotising myopathy</p><p>Tendon disorders sometimes, complicated by rupture</p></td></tr><tr><td style="vertical-align:top"><p><em>Renal and urinary disorders&nbsp; </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haematuria&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Reproductive system and breast disorders&nbsp; </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gynaeco-mastia&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>General disorders and administration site conditions&nbsp; </em></p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oedema</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>&nbsp;1</sup> Frequency will depend on the presence or absence of risk factors (fasting blood glucose &ge; 5.6 mmol/L, BMI &gt;30 kg/m<sup>2</sup>, raised triglycerides, history of hypertension).&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>As with other HMG-CoA reductase inhibitors, the incidence of adverse drug reactions tends to be dose dependent.</p><p>&nbsp;</p><p><strong>Renal effects</strong>: Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients treated with rosuvastatin. Shifts in urine protein from none or trace to ++ or more were seen in &lt;1% of patients at some time during treatment with 10 and 20 mg, and in approximately 3% of patients treated with 40 mg. A minor increase in shift from none or trace to + was observed with the 20 mg dose. In most cases, proteinuria decreases or disappears spontaneously on continued therapy. Review of data from clinical trials and post-marketing experience to date has not identified a causal association between proteinuria and acute or progressive renal disease.</p><p>&nbsp;</p><p>Haematuria has been observed in patients treated with rosuvastatin and clinical trial data show that the occurrence is low.</p><p><strong>&nbsp;</strong></p><p><strong>Skeletal muscle effects</strong>: Effects on skeletal muscle e.g. myalgia, myopathy (including myositis) and, rarely, rhabdomyolysis with and without acute renal failure have been reported in rosuvastatin-treated patients with all doses and in particular with doses &gt; 20 mg.</p><p>&nbsp;</p><p>A dose-related increase in CK levels has been observed in patients taking rosuvastatin; the majority of cases were mild, asymptomatic and transient. If CK levels are elevated (&gt;5xULN), treatment should be discontinued (see section 4.4).&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Liver effects</strong>: As with other HMG-CoA reductase inhibitors, a dose-related increase in transaminases has been observed in a small number of patients taking rosuvastatin; the majority of cases were mild, asymptomatic and transient.</p><p>&nbsp;</p><p>&nbsp;</p><p>The following adverse events have been reported with some statins:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sexual dysfunction.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exceptional cases of interstitial lung disease, especially with long term therapy (see section 4.4).</p><p>&nbsp;</p><p>The reporting rates for rhabdomyolysis, serious renal events and serious hepatic events (consisting mainly of increased hepatic transaminases) is higher at the 40 mg dose.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Creatine kinase elevations &gt;10xULN and muscle symptoms following exercise or increased physical activity were observed more frequently in a 52-week clinical trial of children and adolescents compared to adults (see section 4.4). In other respects, the safety profile of rosuvastatin was similar in children and adolescents compared to adults.</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_4" o:spid="_x0000_s1029"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:85pt;margin-top:46.8pt;width:108.45pt;height:13.3pt;z-index:-251657216;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia:</strong></p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:rect id="Rectangle_x0020_3" o:spid="_x0000_s1028"
 style='position:absolute;left:0;text-align:left;margin-left:85pt;margin-top:36.25pt;
 width:429pt;height:104.9pt;z-index:-251656192;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" stroked="f">
 <w:wrap anchorx="page"/>
</v:rect><![endif]--><img width="572" height="140" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.gif" /><strong>To report any side effect(s):</strong></p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:shape id="Text_x0020_Box_x0020_2"
  o:spid="_x0000_s1027" type="#_x0000_t202" style='position:absolute;
  margin-left:85pt;margin-top:17.55pt;width:429pt;height:104.9pt;z-index:-251655168;
  visibility:visible;mso-wrap-style:square;mso-width-percent:0;
  mso-height-percent:0;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
  mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
  mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
" filled="f" strokeweight=".5pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:3.65pt;margin-right:0in;margin-bottom:
     6.0pt;margin-left:9.9pt'><span lang=EN-GB>NPC<span style='letter-spacing:
     -.2pt'> </span>contact<span style='letter-spacing:-.15pt'> </span>information<span
     style='letter-spacing:-.2pt'> </span>Saudi Arabia:<o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:.45pt'><span lang=EN-GB
     style='font-size:10.5pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>
     <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
     0in;margin-left:43.15pt;text-indent:-18.05pt;line-height:13.15pt;
     mso-line-height-rule:exactly;mso-pagination:none;mso-list:l0 level1 lfo2;
     tab-stops:.6in;text-autospace:none'><![if !supportLists]><span
     style='font-family:"Courier New";mso-fareast-font-family:"Courier New";
     mso-ansi-language:EN-US'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span lang=EN-GB>The<span style='letter-spacing:-.15pt'> </span>National<span
     style='letter-spacing:-.1pt'> </span>Pharmacovigilance<span
     style='letter-spacing:-.15pt'> </span>Centre<span style='letter-spacing:
     -.25pt'> </span>(NPC):</span><span lang=EN-GB style='font-family:"Courier New";
     mso-bidi-font-family:"Times New Roman"'><o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
     0in;margin-left:43.15pt;text-indent:-18.05pt;line-height:12.65pt;
     mso-line-height-rule:exactly;mso-pagination:none;mso-list:l0 level1 lfo2;
     tab-stops:.6in;text-autospace:none'><![if !supportLists]><span
     style='font-family:"Courier New";mso-fareast-font-family:"Courier New";
     mso-ansi-language:EN-US'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span lang=EN-GB>SFDA<span style='letter-spacing:-.1pt'> </span>Call
     Center: 19999</span><span lang=EN-GB style='font-family:"Courier New";
     mso-bidi-font-family:"Times New Roman"'><o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
     0in;margin-left:43.15pt;text-indent:-18.05pt;line-height:12.65pt;
     mso-line-height-rule:exactly;mso-pagination:none;mso-list:l0 level1 lfo2;
     tab-stops:.6in;text-autospace:none'><![if !supportLists]><span
     style='font-family:"Courier New";mso-fareast-font-family:"Courier New";
     mso-ansi-language:EN-US'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span lang=EN-GB>E-mail:<span style='letter-spacing:-.1pt'>
     </span><a href="mailto:npc.drug@sfda.gov.sa"><span style='color:windowtext;
     text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a></span><span
     lang=EN-GB style='font-family:"Courier New";mso-bidi-font-family:"Times New Roman"'><o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
     0in;margin-left:43.15pt;text-indent:-18.05pt;line-height:13.45pt;
     mso-line-height-rule:exactly;mso-pagination:none;mso-list:l0 level1 lfo2;
     tab-stops:.6in;text-autospace:none'><![if !supportLists]><span
     style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Courier New";
     mso-fareast-font-family:"Courier New";mso-ansi-language:EN-US'><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span lang=EN-GB>Website<span
     style='letter-spacing:-.05pt'> </span>ade.sfda.gov.sa</span><span
     lang=EN-GB style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:
     "Courier New";mso-bidi-font-family:"Times New Roman"'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="578" height="146" alt="Text Box: NPC contact information Saudi Arabia:

o	The National Pharmacovigilance Centre (NPC):
o	SFDA Call Center: 19999
o	E-mail: npc.drug@sfda.gov.sa
o	Website ade.sfda.gov.sa
" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC states:</strong></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-GB><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_1" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='width:454.7pt;height:15.9pt;visibility:visible;
 mso-wrap-style:square;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-left-percent:-10001;mso-top-percent:-10001;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight=".48pt">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:.05pt;margin-right:0in;margin-bottom:
    0in;margin-left:5.15pt;margin-bottom:.0001pt;tab-stops:41.15pt'><b
    style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
    mso-bidi-font-size:10.0pt'>-<span style='mso-tab-count:1'>           </span>Please<span
    style='letter-spacing:-.1pt'> </span>contact<span style='letter-spacing:
    -.05pt'> </span>the<span style='letter-spacing:-.05pt'> </span>relevant<span
    style='letter-spacing:-.05pt'> </span>competent<span style='letter-spacing:
    -.2pt'> </span>authority.</span><o:p></o:p></b></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="612" height="27" alt="Text Box: -	Please contact the relevant competent authority." src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-GB><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:454.7pt;
 height:15.9pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment in the event of overdose. In the event of overdose, the patient should be treated symptomatically and supportive measures instituted as required. Liver function and CK levels should be monitored. Haemodialysis is unlikely to be of benefit.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Pharmacotherapeutic group: Lipid modifying agents, plain, HMG-CoA reductase inhibitors, ATC code: C10A A07</p><p><strong>&nbsp;</strong></p><p><u>Mechanism of action </u></p><p>Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor for cholesterol. The primary site of action of rosuvastatin is the liver, the target organ for cholesterol lowering.</p><p>&nbsp;</p><p>Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing uptake and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects </u></p><p>Rosuvastatin<strong> </strong>reduces elevated LDL-cholesterol, total cholesterol and triglycerides and increases HDL-cholesterol. It also lowers ApoB, nonHDL-C, VLDL-C, VLDL-TG and increases ApoA-I (see Table 3). Rosuvastatin<strong> </strong>also lowers the LDL-C/HDL-C, total C/HDL-C and nonHDL-C/HDL-C and the ApoB/ApoA-I ratios.&nbsp;</p><p>&nbsp;</p><p>Table 3 Dose response in patients with primary hypercholesterolaemia (type IIa and IIb) (adjusted mean percent change from baseline)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Dose </strong></p></td><td style="vertical-align:top"><p><strong>N </strong></p></td><td style="vertical-align:top"><p><strong>LDL-C </strong></p></td><td style="vertical-align:top"><p><strong>Total-C </strong></p></td><td style="vertical-align:top"><p><strong>HDL-C </strong></p></td><td style="vertical-align:top"><p><strong>TG </strong></p></td><td style="vertical-align:top"><p><strong>nonHDL-C </strong></p></td><td style="vertical-align:top"><p><strong>ApoB </strong></p></td><td style="vertical-align:top"><p><strong>ApoA-I </strong></p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>-7</p></td><td style="vertical-align:top"><p>-5</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>-3</p></td><td style="vertical-align:top"><p>-7</p></td><td style="vertical-align:top"><p>-3</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>-45</p></td><td style="vertical-align:top"><p>-33</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>-35</p></td><td style="vertical-align:top"><p>-44</p></td><td style="vertical-align:top"><p>-38</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>-52</p></td><td style="vertical-align:top"><p>-36</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>-10</p></td><td style="vertical-align:top"><p>-48</p></td><td style="vertical-align:top"><p>-42</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>-55</p></td><td style="vertical-align:top"><p>-40</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>-23</p></td><td style="vertical-align:top"><p>-51</p></td><td style="vertical-align:top"><p>-46</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>-63</p></td><td style="vertical-align:top"><p>-46</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>-28</p></td><td style="vertical-align:top"><p>-60</p></td><td style="vertical-align:top"><p>-54</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><p>&nbsp;</p><p>A therapeutic effect is obtained within 1 week following treatment initiation and 90% of maximum response is achieved in 2 weeks. The maximum response is usually achieved by 4 weeks and is maintained after that.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>Rosuvastatin<strong> </strong>is effective in adults with hypercholesterolaemia, with and without hypertriglyceridaemia, regardless of race, sex, or age and in special populations such as diabetics, or patients with familial hypercholesterolaemia.</p><p>&nbsp;</p><p>From pooled phase III data, rosuvastatin<strong> </strong>has been shown to be effective at treating the majority of patients with type IIa and IIb hypercholesterolaemia (mean baseline LDL-C about 4.8 mmol/L) to recognised European Atherosclerosis Society (EAS; 1998) guideline targets; about 80% of patients treated with 10 mg reached the EAS targets for LDL-C levels (&lt;3 mmol/L).</p><p>&nbsp;</p><p>In a large study, 435 patients with heterozygous familial hypercholesterolaemia were given rosuvastatin from 20 mg to 80 mg in a force-titration design. All doses showed a beneficial effect on lipid parameters and treatment to target goals. Following titration to a daily dose of 40 mg (12 weeks of treatment), LDL-C was reduced by 53%. 33% of patients reached EAS guidelines for LDL-C levels (&lt;3 mmol/L).</p><p>&nbsp;</p><p>In a force-titration, open label trial, 42 patients with homozygous familial hypercholesterolaemia were evaluated for their response to rosuvastatin 20 &ndash; 40 mg. In the overall population, the mean LDL-C reduction was 22%.</p><p>&nbsp;</p><p>In clinical studies with a limited number of patients, rosuvastatin has been shown to have additive efficacy in lowering triglycerides when used in combination with fenofibrate and in increasing HDL-C levels when used in combination with niacin (see section 4.4).</p><p>&nbsp;</p><p>In a multi-centre, double-blind, placebo-controlled clinical study (METEOR), 984 patients between 45 and 70 years of age and at low risk for coronary heart disease (defined as Framingham risk &lt;10% over 10 years), with a mean LDL-C of 4.0 mmol/L (154.5 mg/dL), but with subclinical atherosclerosis (detected by Carotid Intima Media Thickness) were randomised to 40 mg rosuvastatin once daily or placebo for 2 years. Rosuvastatin significantly slowed the rate of progression of the maximum CIMT for the 12 carotid artery sites compared to placebo by -0.0145 mm/year [95% confidence interval -0.0196, -0.0093; p&lt;0.0001]. The change from baseline was -0.0014 mm/year (-0.12%/year (non-significant)) for rosuvastatin compared to a progression of +0.0131 mm/year (1.12%/year (p&lt;0.0001)) for placebo. No direct correlation between CIMT decrease and reduction of the risk of cardiovascular events has yet been demonstrated. The population studied in METEOR is low risk for coronary heart disease and does not represent the target population of rosuvastatin 40 mg. The 40 mg dose should only be prescribed in patients with severe hypercholesterolaemia at high cardiovascular risk (see section 4.2).</p><p>&nbsp;</p><p>In the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) study, the effect of rosuvastatin on the occurrence of major atherosclerotic cardiovascular disease events was assessed in 17,802 men (&ge;&nbsp;50 years) and women (&ge;&nbsp;60 years).</p><p>&nbsp;</p><p>Study participants were randomly assigned to placebo (n=8901) or rosuvastatin 20 mg once daily (n=8901) and were followed for a mean duration of 2 years.</p><p>&nbsp;</p><p>LDL-cholesterol concentration was reduced by 45% (p&lt;0.001) in the rosuvastatin group compared to the placebo group.</p><p>&nbsp;</p><p>In a post-hoc analysis of a high-risk subgroup of subjects with a baseline Framingham risk score &gt;20% (1558 subjects) there was a significant reduction in the combined end-point of cardiovascular death, stroke and myocardial infarction (p=0.028) on rosuvastatin treatment versus placebo. The absolute risk reduction in the event rate per 1000 patient-years was 8.8. Total mortality was unchanged in this high risk group (p=0.193). In a post-hoc analysis of a high-risk subgroup of subjects (9302 subjects total) with a baseline SCORE risk &ge;&nbsp;5% (extrapolated to include subjects above 65 years) there was a significant reduction in the combined end-point of cardiovascular death, stroke and myocardial infarction (p=0.0003) on rosuvastatin treatment versus placebo. The absolute risk reduction in the event rate was 5.1 per 1000 patient-years. Total mortality was unchanged in this high risk group (p=0.076).</p><p>&nbsp;</p><p>In the JUPITER trial there were 6.6% of rosuvastatin and 6.2% of placebo subjects who discontinued use of study medicinal product due to an adverse event. The most common adverse events that led to treatment discontinuation were: myalgia (0.3% rosuvastatin, 0.2% placebo), abdominal pain (0.03% rosuvastatin, 0.02% placebo) and rash (0.02% rosuvastatin, 0.03% placebo). The most common adverse events at a rate greater than or equal to placebo were urinary tract infection (8.7% rosuvastatin, 8.6% placebo), nasopharyngitis (7.6% rosuvastatin, 7.2% placebo), back pain (7.6% rosuvastatin, 6.9% placebo) and myalgia (7.6% rosuvastatin, 6.6% placebo).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>In a double-blind, randomized, multi-centre, placebo-controlled, 12-week study (n=176, 97 male and 79 female) followed by a 40-week (n=173, 96 male and 77 female), open-label, rosuvastatin dose-titration phase, patients 10-17 years of age (Tanner stage II-V, females at least 1 year post-menarche) with heterozygous familial hypercholesterolaemia received rosuvastatin 5, 10 or 20 mg or placebo daily for 12 weeks and then all received rosuvastatin daily for 40 weeks. At study entry, approximately 30% of the patients were 10-13 years and approximately 17%, 18%, 40%, and 25% were Tanner stage II, III, IV, and V, respectively.</p><p>&nbsp;</p><p>LDL-C was reduced 38.3%, 44.6%, and 50.0% by rosuvastatin 5, 10 and 20 mg, respectively, compared to 0.7% for placebo.</p><p>&nbsp;</p><p>At the end of the 40-week, open-label, titration to goal, dosing up to a maximum of 20 mg once daily, 70 of 173 patients (40.5%) had achieved the LDL-C goal of less than 2.8 mmol/L.</p><p>&nbsp;</p><p>After 52 weeks of study treatment, no effect on growth, weight, BMI or sexual maturation was detected (see section 4.4). This trial (n=176) was not suited for comparison of rare adverse drug events.</p><p>&nbsp;</p><p>Rosuvastatin was also studied in a 2-year open-label, titration-to-goal study in 198 children with heterozygous familial hypercholesterolaemia aged 6 to 17 years (88 male and 110 female, Tanner stage &lt;II-V). The starting dose for all patients was 5 mg rosuvastatin once daily. Patients aged 6 to 9 years (n=64) could titrate to a maximum dose of 10 mg once daily and patients aged 10 to 17 years (n=134) to a maximum dose of 20 mg once daily.</p><p>&nbsp;</p><p>After 24 months of treatment with rosuvastatin, the LS mean percent reduction from the baseline value in LDL-C was - 43% (Baseline: 236 mg/dL, Month 24: 133 mg/dL). For each age group, the LS mean percent reductions from baseline values in LDL-C were -43% (Baseline: 234 mg/dL, Month 24: 124 mg/dL), -45% (Baseline: 234 mg/dL, 124 mg/dL), and -35% (Baseline: 241 mg/dL, Month 24: 153 mg/dL) in the 6 to &lt;10, 10 to &lt;14, and 14 to &lt;18 age groups, respectively.</p><p>&nbsp;</p><p>Rosuvastatin 5 mg, 10 mg, and 20 mg also achieved statistically significant mean changes from baseline for the following secondary lipid and lipoprotein variables: HDL-C, TC, non-HDL-C, LDL-C/HDL-C, TC/HDL-C, TG/HDL-C, non-HDL-C/HDL-C, ApoB, ApoB/ApoA-1. These changes were each in the direction of improved lipid responses and were sustained over 2 years.</p><p>&nbsp;</p><p>No effect on growth, weight, BMI or sexual maturation was detected after 24 months of treatment (see section 4.4).</p><p>&nbsp;</p><p>Rosuvastatin was studied in a randomised, double-blind, placebo-controlled, multicenter, cross-over study with 20 mg once daily versus placebo in 14 children and adolescents (aged from 6 to 17 years) with homozygous familial hypercholesterolaemia. The study included an active 4-week dietary lead-in phase during which patients were treated with rosuvastatin 10 mg, a cross-over phase that consisted of a 6-week treatment period with rosuvastatin 20 mg preceded or followed by a 6-week placebo treatment period, and a 12-week maintenance phase during which all patients were treated with rosuvastatin 20 mg. Patients who entered the study on ezetimibe or apheresis therapy continued the treatment throughout the entire study.</p><p>&nbsp;</p><p>A statistically significant (p=0.005) reduction in LDL-C (22.3%, 85.4 mg/dL or 2.2 mmol/L) was observed following 6 weeks of treatment with rosuvastatin 20 mg versus placebo. Statistically significant reductions in Total-C (20.1%, p=0.003), non-HDL-C (22.9%, p=0.003), and ApoB (17.1%, p=0.024) were observed. Reductions were also seen in TG, LDL-C/HDL-C, Total-C/HDL-C, non-HDL-C/HDL-C, and ApoB/ApoA-1 following 6 weeks of treatment with rosuvastatin 20 mg versus placebo. The reduction in LDL-C after 6 weeks of treatment with rosuvastatin 20 mg following 6 weeks of treatment with placebo was maintained over 12 weeks of continuous therapy.</p><p>&nbsp;</p><p>One patient had a further reduction in LDL-C (8.0%), Total-C (6.7%) and non-HDL-C (7.4%) following 6 weeks of treatment with 40 mg after up-titration.</p><p>&nbsp;</p><p>During an extended open-label treatment in 9 of these patients with 20 mg rosuvastatin for up to 90 weeks the LDL-C reduction was maintained in the range of -12.1% to -21.3%.</p><p>&nbsp;</p><p>In the 7 evaluable children and adolescent patients (aged from 8 to 17 years) from the forced titration open-label study with homozygous familial hypercholesterolaemia (see above), the percent reduction in LDL-C (21.0%), Total-C (19.2%) and non-HDL-C (21.0%) from baseline following 6 weeks of treatment with rosuvastatin 20 mg was consistent with that observed in the aforementioned study in children and adolescents with homozygous familial hypercholesterolaemia.</p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with rosuvastatin in all subsets of the paediatric population in the treatment of homozygous familial hypercholesterolaemia, primary combined (mixed) dyslipidaemia and in the prevention of cardiovascular events (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><strong>Absorption:</strong> Maximum rosuvastatin plasma concentrations are achieved approximately 5 hours after oral administration. The absolute bioavailability is approximately 20%.</p><p>&nbsp;</p><p><strong>Distribution:</strong> Rosuvastatin is taken up extensively by the liver which is the primary site of cholesterol synthesis and LDL-C clearance. The volume of distribution of rosuvastatin is approximately 134 L. Approximately 90% of rosuvastatin is bound to plasma proteins, mainly to albumin.</p><p>&nbsp;</p><p><strong>Biotransformation:</strong> Rosuvastatin undergoes limited metabolism (approximately 10%). <em>In vitro</em> metabolism studies using human hepatocytes indicate that rosuvastatin is a poor substrate for cytochrome P450-based metabolism. CYP2C9 was the principal isoenzyme involved, with 2C19, 3A4 and 2D6 involved to a lesser extent. The main metabolites identified are the N-desmethyl and lactone metabolites. The N-desmethyl metabolite is approximately 50% less active than rosuvastatin whereas the lactone form is considered clinically inactive. Rosuvastatin accounts for greater than 90% of the circulating HMG-CoA reductase inhibitor activity.</p><p>&nbsp;</p><p><strong>Elimination:</strong> Approximately 90% of the rosuvastatin dose is excreted unchanged in the faeces (consisting of absorbed and non-absorbed active substance) and the remaining part is excreted in urine. Approximately 5% is excreted unchanged in urine. The plasma elimination half-life is approximately 19 hours. The elimination half-life does not increase at higher doses. The geometric mean plasma clearance is approximately 50 litres/hour (coefficient of variation 21.7%). As with other HMG-CoA reductase inhibitors, the hepatic uptake of rosuvastatin involves the membrane transporter OATP-C. This transporter is important in the hepatic elimination of rosuvastatin.</p><p>&nbsp;</p><p><strong>Linearity:</strong> Systemic exposure of rosuvastatin increases in proportion to dose. There are no changes in pharmacokinetic parameters following multiple daily doses.&nbsp;</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Age and sex:</em> There was no clinically relevant effect of age or sex on the pharmacokinetics of rosuvastatin in adults. The exposure in children and adolescents with heterozygous familial hypercholesterolaemia appears to be similar to or lower than that in adult patients with dyslipidemia (see &ldquo;Paediatric population&rdquo; below).</p><p>&nbsp;</p><p><em>Race:</em> Pharmacokinetic studies show an approximate 2-fold elevation in median AUC and C<sub>max</sub> in Asian subjects (Japanese, Chinese, Filipino, Vietnamese and Koreans) compared with Caucasians; Asian-Indians show an approximate 1.3-fold elevation in median AUC and C<sub>max</sub>. A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics between Caucasian and Black groups.</p><p>&nbsp;</p><p><em>Renal impairment:</em> In a study in subjects with varying degrees of renal impairment, mild to moderate renal disease had no influence on plasma concentration of rosuvastatin or the N-desmethyl metabolite. Subjects with severe impairment (CrCl &lt;30 ml/min) had a 3-fold increase in plasma concentration and a 9-fold increase in the N-desmethyl metabolite concentration compared to healthy volunteers. Steady-state plasma concentrations of rosuvastatin in subjects undergoing haemodialysis were approximately 50% greater compared to healthy volunteers.</p><p>&nbsp;</p><p><em>Hepatic impairment:</em> In a study with subjects with varying degrees of hepatic impairment there was no evidence of increased exposure to rosuvastatin in subjects with Child-Pugh scores of 7 or below. However, two subjects with Child-Pugh scores of 8 and 9 showed an increase in systemic exposure of at least 2-fold compared to subjects with lower Child-Pugh scores. There is no experience in subjects with Child-Pugh scores above 9.</p><p>&nbsp;</p><p><em>Genetic polymorphisms:</em> Disposition of HMG-CoA reductase inhibitors, including rosuvastatin, involves OATP1B1 and BCRP transporter proteins. In patients with SLCO1B1 (OATP1B1) and/or ABCG2 (BCRP) genetic polymorphisms there is a risk of increased rosuvastatin exposure. Individual polymorphisms of SLCO1B1 c.521CC and ABCG2 c.421AA are associated with a higher rosuvastatin exposure (AUC) compared to the SLCO1B1 c.521TT or ABCG2 c.421CC genotypes. This specific genotyping is not established in clinical practice, but for patients who are known to have these types of polymorphisms, a lower daily dose of Roxardio is recommended.</p><p>&nbsp;</p><p><em>Paediatric population:</em> Two pharmacokinetic studies with rosuvastatin (given as tablets) in paediatric patients with heterozygous familial hypercholesterolaemia 10 &ndash; 17 or 6 &ndash; 17 years of age (total of 214 patients) demonstrated that exposure in paediatric patients appears comparable to or lower than that in adult patients. Rosuvastatin exposure was predictable with respect to dose and time over a 2-year period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity and carcinogenicity potential. Specific tests for effects on hERG have not been evaluated. Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels were as follows: In repeated-dose toxicity studies histopathologic liver changes likely due to the pharmacologic action of rosuvastatin were observed in mouse, rat, and to a lesser extent with effects in the gall bladder in dogs, but not in monkeys. In addition, testicular toxicity was observed in monkeys and dogs at higher dosages.</p><p>Reproductive toxicity was evident in rats, with reduced litter sizes, litter weight and pup survival observed at maternally toxic doses where systemic exposures were several times above the therapeutic exposure level.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Tablet contents</strong>:</p><p>Lactose</p><p>Silica, Colloidal Anhydrous</p><p>Silicified Microcrystalline Cellulose&nbsp;</p><p>Maize Starch</p><p>Talc</p><p>Sodium Stearyl Fumarate</p><p>&nbsp;</p><p><strong>Tablet coat</strong>:</p><p>Hypromellose</p><p>Mannitol E 421</p><p>Macrogol 6000</p><p>Talc</p><p>Titanium dioxide E 171</p><p>Ferric oxide, yellow E 172</p><p>Ferric oxide, red E 172</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C, in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>OPA-Al-PVC/Al blisters: </strong>30, film-coated tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>No special requirements.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sandoz GmbH
Biochemiestrasse 10, 6250- Kundl Austria

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>